Genetic variants in arachidonic acid pathway genes associated with NSAIDs-exacerbated respiratory disease

Aim: NSAIDs are the most frequent cause of hypersensitivity drug reactions. We have examined the association between NSAIDs-exacerbated respiratory disease (NERD) and genetic variants in arachidonic acid metabolism genes. **Patients & methods:** We included 250 NERD patients, 260 NSAID-tolerant asthmatic (NTA) subjects and 315 healthy controls. **Results:** Significant associations with NERD were identified for: *ALOX15* rs3892408 C/C homozygous genotype (NERD vs NTA; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0001, pc = 0.0011; NERD vs controls; p = 0.0004, pc = 0.0011; NERD vs controls; p = 0.0009, pc = 0.0091; NERD vs controls; p = 0.0064, pc = 0.045). Differences in *ALOX5* copy number variations were also found (NERD vs NTA; p = 0.010; NERD vs controls; p = 0.0001). **Conclusion:** These results improve our understanding of the underlying mechanisms of NERD and may help develop a predictive test for this pathology.

Original submitted 3 November 2014; Revision submitted 2 April 2015

Keywords: copy number variations • hypersensitivity drug reactions • NSAIDs • NSAIDs-exacerbated respiratory disease • polymorphisms

Hypersensitivity drug reactions (HDRs) are an important health problem affecting patients of all ages [1]. They may not be predicted before postmarketing surveillance and constitute one of the most frequent reasons for consultations in allergy services, particularly for adults, requiring many resources, including trained personnel and an appropriate setting for their correct evaluation and diagnosis [2]. A recent study carried out by our group has shown that NSAIDs are currently the drugs most frequently involved in HDRs, surpassing betalactam antibiotics [3].

Different types of HDRs to NSAIDs can be identified depending on the symptoms, number of NSAIDs involved and the presence of an underlying pathology. Two main groups can be distinguished: in the first, inflammatory mediators are produced in the absence of a specific immunological mechanism (cross intolerant [CI]). This includes several enti-

ties that are expressed with varied clinical manifestations: NSAIDs-exacerbated respiratory disease (NERD), previously known as ASA-induced asthma or ASA-exacerbated respiratory disease; NSAIDs-exacerbated cutaneous disease (NECD), manifesting as urticaria and angioedema in patients with chronic spontaneous urticaria; and NSAIDsinduced urticaria/angiodema (NIUA), occurring in patients without preexisting chronic spontaneous urticaria. In addition, combined reactions can occur involving respiratory airways and the skin, also known as blended reactions [4]. The second group of entities encompasses reactions involving immunological mechanisms (selective responders). These can be further classified into: Single-NSAID-induced urticaria/angioedema or anaphylaxis (SNIUAA) attributed to specific IgE responses; and Single-NSAID-induced delayed reactions (SNIDR) induced by sensiPedro Ayuso^{4,1,2}, María del Carmen Plaza-Serón^{4,1,2}, Natalia Blanca-López², Inmaculada Doña³, Paloma Campo³, Gabriela Canto², José Julio Laguna⁴, Joan Bartra⁵, Victor Soriano-Gomis⁶, Miguel Blanca³, José A Cornejo-García^{*,1,3} & James R Perkins¹

¹Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain ²Allergy Service, Infanta Leonor Hospital, Madrid, Spain ³Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga, Spain ⁴Allergy Service, Cruz Roja Central Hospital, Madrid, Spain ⁵Allergy Unit, Pneumology & Allergy Department, Hospital Clinic, Barcelona, Spain ⁶Allergy Service, Alicante General Hospital, Alicante, Spain *Author for correspondence: Tel.: +34 952 290 346 Fax: +34 952 290 302 josea.cornejo@gmail.com [‡]Authors contributed equally



Pharmacogenomics



tized T cells [5]. Our group recently published the analysis of a large cohort of almost 700 patients, showing that 76% of NSAIDs reactions belonged to the CI type compared with 24% for selective reactions [6]. Further classification has been proposed in order to better define the different phenotypes of NSAID-hypersensitive patients [7].

In this work, we will focus on NERD. Its prevalence is estimated to range from 0.3 to 0.9% in the general population, 4.3 to 11% in adult asthmatics and is about 25% in patients with asthma and nasal polyposis [8,9]. In NERD patients, NSAID intake induces nasal congestion and rhinorrhea, followed by difficulty breathing and progressive nasal obstruction within a short time interval [10]. This entity is characterized by an adult onset and patients have a previous history of bronchial asthma that is very frequently associated with chronic rhinosinusitis and/or nasal polyposis [11]. The gold standard for diagnosis is oral challenge; however, this is a time-consuming procedure and is not risk-free. The mechanism of NERD has been attributed to the inhibition of prostaglandin-endoperoxide synthases (PTGS) by NSAIDs in susceptible individuals, causing a reduction in prostaglandin E₂ production and shunting arachidonic acid metabolism toward the lipooxygenase pathway, resulting in the release of cysteinyl leukotrienes (CysLTs) [12]. This hypothesis is consistent with previous studies that have reported CysLT overproduction in NERD patients [13,14]. The first genetic studies showed functional variation in LTC4S and ALOX5 genes to be associated with NERD [15,16]. Associated genetic variants have also been found in the leukotriene receptors CysLTR1 and CysLTR2, PTGS2 and prostaglandin receptor genes [17]. However, many of these associations have been inconsistently replicated, possibly due to the limited number of gene studied, and most studies have focused on Asian populations [17]. With regards to European populations, previous work by our group investigating genetic variation in NIUA patients found statistically significant associations for several SNPs in enzymes and receptors from the arachidonic acid pathway [18]. Copy number variations (CNVs), variations in the number of copies of a section of DNA in the genome, can affect gene expression and be associated with disease susceptibility [19]. However, they have not yet been studied in relation to NSAID hypersensitivity and their role as possible genetic markers for NERD has not been investigated.

In this work, we have investigated the association of various SNPs and CNVs in arachidonic acid-related genes with NERD, in a Spanish population. We found a number of significant variants that will be of use for establishing the genetic basis of NERD and enable us to compare and contrast NERD with other NSAIDs-hypersensitivity pathologies such as NIUA and NECD.

Patients & methods Subjects

We included a total of 250 NERD patients, 260 NSAID-tolerant asthmatic (NTA) patients and 315 unrelated healthy subjects. These individuals were recruited between 2007 and 2013 from the Allergy services of six Spanish public hospitals. They are integrated in the national research network RIRAAF (Table 1).

All patients were diagnosed with asthma according to the Global Initiative for Asthma (GINA) guidelines [20]. NERD patients were required to have a history of at least two episodes of respiratory symptoms after NSAID intake and a positive nasal challenge with lysine-acetylsalicylate (L-ASA), as previously described [21]. The NTA group consisted of asthmatic patients who tolerated NSAIDs. Healthy subjects had no past history of asthma or NSAID hypersensitivity, a FEV, greater than 80% of the predicted value and a PC₂₀ with methacholine greater than 25 mg/ml [22]. The presence of rhinosinusitis and nasal polyps was evaluated using a paranasal sinus X-ray and rhinoscopy. L-ASA was administered to NTA and healthy subjects to confirm tolerance before inclusion in the study.

Skin prick testing (SPT) was performed with a panel of 30 prevalent inhalant allergens and total serum IgE was measured using the CAP system (Phadia, Uppsala, Sweden). Atopy was defined as one or more positive SPT results or a total IgE value \geq 130 kU/l. Eosinophil cationic protein and serum tryptase were measured by UniCAP (Phadia), and eosinophil count by flow cytometry.

Genotyping

A total of 33 SNPs in PTGS1 (rs5789, rs5794, rs1236913, rs10306108, rs3842787, rs10306135), PTGS2 (rs689465, rs689466), ALOX5 (rs2115819, rs3780894, rs4986832), ALOX5AP(rs1132340), ALOX12(rs434473, rs1126667), ALOX15 (rs3892408, rs11568131), LTC4S (rs730012), CYSLTR1 (rs320995, rs2806489), CYSLTR2 (rs912278), PTGER1 (rs3810253, rs3810255), PTGER2 (rs17197, rs1254598, rs1353411, rs2075797), PTGER3 (rs959), PTGER4 (rs4495224, rs7720838, rs45613037), PTGDR (rs8004654, rs34236606) and PTGFR (rs3753380) genes were studied. They were selected on the basis of their minor allele frequencies (MAF > 0.05) in European populations from the HapMap [23], 1000 Genomes project [24] or dbSNP databases [25] and their

Table 1. Clinical and demographic	c characteristics of	study subjects.			
	NERD (n = 250)	NTA (n = 260)	Controls (n = 315)	p-value (NERD vs controls)	p-value (NERD vs NTA)
Age (mean, SD)	(39.87,17.55)	(38.15,12.80)	(39.16,17.74)	0.8010	0.2054
Sex (% females)	65.70	59.68	62.45	0.4903	0.2104
Personal history					
Rhinitis (%)	63.12	94.31	na	na	<0.0001
Asthma (%)	67.43	100	na	na	<0.0001
Polyposis (%)	29.31	9.87	na	na	<0.0001
FEV1%	87.71	89.89	na	na	0.6954
Culprit NSAIDs (%)					
Propionic acid derivates	31.64	na	na	na	na
ASA	25.99	na	na	na	na
Metamizol	18.64	na	na	na	na
Paracetamol	4.80	na	na	na	na
Diclofenac	6.50	na	na	na	na
Type of reaction (%)					
Rhinitis	12.73	na	na	na	na
Asthma	57.58	na	na	na	na
Upper airways	7.27	na	na	na	na
Rhinitis + asthma	22.42	na	na	na	na
Total IgE (median, range) (kU/l)	82.0 (44.0–208.0)	228.0 (108.0–543.0)	27.5 (11.0–63.25)	<0.0001	<0.0001
SPT (% positive skin prick test)	60.8%	94.82%	34.98%	<0.0001	<0.0001
Phleum	5.6	3.21	6.36	0.7841	0.2832
Lolium	24.0	3.66	6.36	<0.0001	<0.0001
Olea europaea	24.0	71.55	8.63	<0.0001	<0.0001
Dermatophagoides pteronyssinus	20.0	67.43	7.27	0.0004	<0.0001
Lepidoglyphus destructor	6.4	67.43	2.72	0.0952	<0.0001
Dog	16.8	44.03	2.72	<0.0001	<0.0001
Cat	17.6	44.49	5	0.0001	<0.00010
ASA: Acetylsalicylate; IgE: Immunoglobulin E; r	na: Not applicable; NERD:	NSAIDs-exacerbated respirato	ry disease; NTA: NSAID-to	olerant asthmatic	patients; SPT: Skin

prick testing.

possible functional role according to previous reports and information obtained from SNPinfo [26].

Genotyping was carried out by PCR in a 7500 Fast Real-Time PCR System using TaqMan[®] allelic discrimination assays (Applied Biosystems, CA, USA). All samples were determined in triplicate and genotypes were assigned using 7500 software 2.0.1. CNVs were analyzed using TaqMan copy number assays (Applied Biosciences), which were designed to hybridize within the open reading frame in each gene. Amplification was carried out as described by the manufacturer, using RNAse P as a copy number reference assay. Results were analyzed using the CopyCaller Software (Applied Biosciences).

Statistical analysis

Demographic and clinical data were analyzed using the Mann-Whitney U-test implemented in SPSS 15.0 (SPSS Inc., IL, USA). The Hardy–Weinberg equilibrium was evaluated with the DeFinetti program [27]. Allelic and genotypic frequency analyses were performed by logistic regression using allelic, heterozygous and homozygous dominant and recessive models and adjusting for the atopic status (Table 2). Correction for multiple testing was performed by calculating the false-discovery rate (FDR) using QVALUE [28]. A corrected p-value (q-value) of ≤ 0.05 was considered statistically significant. Haplotype reconstruction was performed using Haploview 4.2 [29]. The statistical power

ALOX state OR (95%, CI) pondue OR (95%, CI) ALOX x, 211513 A.G 30.5 0.160 0.67 (0.37-1.19) 0.900 0.97 (0.39-1.53) ALOX A.G 33.5 0.160 0.67 (0.37-1.19) 0.900 0.97 (0.39-1.53) ALOX ALE 21.7 19.7 21.0 9.25 0.64 0.90 0.91 (0.29-1.53) ALOX ALE 21.9 9.7 0.00 0.83 (0.49-1.44) 0.400 17.2 (0.77-1.94) ALE ALE 23.0 3.04 3.04 3.04 3.04 3.04 3.04 3.04 3.04 3.04 3.04 3.02 3.04	ALOX5rs2115819A/AALOX5rs2115819A/GA/GG/GG/GA/AA/Blele frequenA/GA/Blele frequenA/GA/Blele frequenA/GA/Blele frequenA/GA/DA/GA/DA/GA/DA/GALOX5APrs1132340ALOX72rs434473ALOX72rs434473ALOX72rs433420ALOX73rs1126667ALOX75rs1126667ALOX75rs3892408ALOX75rs484473ALOX75rs484473ALOX75rs484473<	29.6 29.6 48.7 21.7 21.7 65.2 65.2 32.2 2.6 32.2 64.7 64.7 56	33.6 46.6 19.7 43.0 66.8 30.4 18.0 18.0 60.6 335.0 3.5	30.5 48 F	n-value			00 (010) 00
ALOX5 1x11561 ALA 29.6 33.6 30.5 0160 097 (0.37-1.19) 0.900 097 (0.39-1.63) ALOX 21.7 43.7 46.5 48.5 48.5 0.641 0.38 (0.55-1.41) 0.91 0.97 (0.52-1.50) Allele frequency 6.0 43.0 45.25 0.641 0.38 (0.55-1.41) 0.91 0.27 (0.52-1.50) Allele frequency 6.0 30.4 4.3 0.88 0.400 1.12 (0.52-1.50) Allele frequency 6.0 2.0 3.45 0.98 0.990 0.9400 1.38 (0.66-2.00) Allele frequency 18.7 18.6 0.93 0.490 0.400 1.30 (0.52-1.50) Allele frequency 18.7 18.6 0.93 0.45 0.300 0.400 1.30 (0.52-1.50) Allele frequency 19.0 2.15 2.23 0.667 1.48 (0.65-1.60) 1.48 (0.52-1.50) Allele frequency 9.0 2.15 2.23 0.667 1.42 (0.65-2.60) 1.41 (0.55-2.51) 1.44 (0.55-2.51)	ALOX5rs2115819A/AA/GG/GG/GG/GAllele frequenA/GAllele frequenA/GA/GG/GAllele frequenA/GAllele frequenA/GALOX5APrs1132340ALOX5APrs1132340ALOX5APrs1132340ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs434473ALOX12rs3392408ALOX15rs3892408ALOX15rs484408ALOX15rs484408ALOX15rs484408ALOX15rs484408ALOX15rs484408 <th>29.6 48.7 21.7 21.7 55.2 55.2 32.2 2.6 32.2 64.7 64.7 56</th> <th>33.6 46.6 19.7 43.0 66.8 30.4 18.0 60.6 3.5 3.5</th> <th>30.5 48 F</th> <th></th> <th>OK (22% CI)</th> <th>p-vaiue</th> <th>UK (95% CI)</th>	29.6 48.7 21.7 21.7 55.2 55.2 32.2 2.6 32.2 64.7 64.7 56	33.6 46.6 19.7 43.0 66.8 30.4 18.0 60.6 3.5 3.5	30.5 48 F		OK (22% CI)	p-vaiue	UK (95% CI)
ΛG 813 46.6 61.3 0.30 </th <th>AIG A/G G/G G/G Allele frequen A/A rs3780894 A/A A/G A/G A/OX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/G ALOX12 rs4334473 A/G ALOX12 rs433427 A/G ALOX13 rs433240 A/G ALOX14 rs3892408 A/G ALOX15 rs3892408 C/C</th> <th>48.7 21.7 21.7 65.2 65.2 32.2 2.6 2.6 64.7 64.7 56</th> <th>46.6 19.7 43.0 66.8 30.4 2.8 18.0 60.6 335.0 3.5</th> <th>101</th> <th>0.160</th> <th>0.67 (0.37–1.19)</th> <th>0.900</th> <th>0.97 (0.59–1.58)</th>	AIG A/G G/G G/G Allele frequen A/A rs3780894 A/A A/G A/G A/OX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/G ALOX12 rs4334473 A/G ALOX12 rs433427 A/G ALOX13 rs433240 A/G ALOX14 rs3892408 A/G ALOX15 rs3892408 C/C	48.7 21.7 21.7 65.2 65.2 32.2 2.6 2.6 64.7 64.7 56	46.6 19.7 43.0 66.8 30.4 2.8 18.0 60.6 335.0 3.5	101	0.160	0.67 (0.37–1.19)	0.900	0.97 (0.59–1.58)
International conditional conditiconal conditional conditional conditional conditional con	G/G Allele frequen rs3780894 A/A Alfele frequen A/G A/G A/G Alfele frequen A/G Alfele frequen A/G Alfele frequen A/G Alfele frequen A/G ALOX5AP rs1132340 A/A ALOX12 rs1132340 A/A ALOX12 rs3392408 A/G ALOX12 rs3392408 A/G ALOX13 rs3892408 C/C ALOX15 rs3892408 C/C	21.7 21.7 65.2 32.2 32.2 2.6 64.7 64.7 56	19.7 43.0 66.8 30.4 2.8 18.0 60.6 335.0	6.04				
Mile frequency 450 452 0.641 0.89 0.55-141 0.97 0.65-150 A/G 52.2 66.8 61.1 0.330 0.44 0.400 1.22 0.77-149 A/G 21.2 0.34 4.4 0.530 0.44 0.400 1.22 0.77-149 A/G 21.2 0.74 0.88 0.44 0.910 0.3100 1.28 0.88-2.04 A/G 21.6 28.6 0.88 0.790 0.405 1.88<(0.65-2.03) 1.88 0.55-141 1.28<(0.77-145) 1.28<(0.85-169) 1.28<(0.85-2.03) A/G 21.6 28.6 0.58 0.790 0.400 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03) 1.28<(0.85-2.03)	Allele frequen rs3780894 A/A A/G A/G A/G A/G A/Blele frequen A/G rs4986832 A/A A/Blele frequen A/G A/D A/G A/D A/G A/D A/G A/D A/A A/D A/A ALOX5AP rs1132340 A/A ALOX52 rs1132340 A/A ALOX72 rs413437 A/A ALOX12 rs434473 A/A ALOX12 rs41326667 A/A ALOX12 rs1126667 A/A ALOX12 rs3892408 C/G ALOX15 rs3892408 C/C	ency 46.0 65.2 32.2 2.6 ency 18.7 64.7 32.8 32.8	43.0 66.8 30.4 2.8 18.0 60.6 3.5 3.5	21.0				
1 15378036 AA 65.2 66.8 61.1 0.331 0.400 1.22 0.201 AG 32.2 30.4 34.5 AA	rs3780894 A/A A/G A/G A/G G/G Allele frequen A/G rs4986832 A/A Allele frequen A/G ALDX5AP rs1132340 A/G ALDX5AP rs1132340 A/A ALDX12 rs1132340 A/A ALDX12 rs41473 A/A ALDX12 rs434473 A/A ALDX13 rs434473 A/A ALDX15 rs3892408 C/C ALDX15 rs3892408 C/C	65.2 32.2 2.6 32.6 64.7 32.8 32.8	66.8 30.4 2.8 18.0 60.6 36.0 3.5	45.25	0.641	0.89 (0.56–1.41)	0.911	0.97 (0.62–1.50)
$/\sqrt{6}$ 3.2 3.4 3.4 3.4 3.6	A/G A/G G/G G/G Allele frequen A/G Allele frequen A/G ALOX5AP rs1132340 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/G ALOX13 rs434473 A/G ALOX13 rs434473 A/G ALOX13 rs3892408 C/C	32.2 2.6 18.7 64.7 32.8 2.6	30.4 2.8 18.0 60.6 3.5	61.1	0.530	0.84 (0.49–1.44)	0.400	1.22 (0.77–1.94)
G(G 2.6 2.8 4.4 Ible frequency 18.7 18.0 21.65 0.882 0.94 (0.33-1.63) 0.588 1.18 (0.66-2.04) A/A 2.1 6.47 6.65 5.93 0.790 1.07 (0.63-1.81) 0.300 1.28 (0.80-2.03) A/A 2.1 3.6 3.5 3.5 0.55 0.55 0.567 1.10 (0.63-1.81) 0.300 1.28 (0.80-2.03) A/A 2.1 3.6 3.5 0.55 0.55 0.567 1.18 (0.65-2.09) 1.28 (0.80-2.03) A/A 2.1 2.5 3.5 0.55 0.59 0.59 1.41 (0.55-2.52) A/A 0.4 0.5 0.55 0.59 0.59 0.59 1.41 (0.65-2.92) A/C 0.4 0.5 0.50 0.54 0.53 0.54 1.41 (0.55-2.52) A/A 0.4 0.5 0.56 0.58 0.56 0.56 0.56 0.56 A/A 0.5 0.5 0.50 0.564	G/G rs4986832 A/A Allele frequen A/G	2.6 ency 18.7 64.7 32.8 2.6	2.8 18.0 60.6 36.0 3.5	34.5				
Allel frequency 18.0 21.65 0.882 0.94 (0.53-1.68) 0.588 118 (0.68-2.03) A(G 32.3 56.0 35.7 6.7 6.0.5 59.8 0.790 1.07 (0.63-181) 0.300 1.28 (0.80-2.03) A(G 32.8 35.0 35.7 4.5 3.5 3.5 1.07 (0.63-1.81) 0.300 1.28 (0.80-2.03) A(G 2.8 3.50 35.0 35.7 0.667 1.18 (0.67-2.09) 0.490 1.24 (0.52-2.15) A(D 915 2.15 87.0 0.667 1.42 (0.63-3.20) 0.340 1.41 (0.66-2.213) A(D 916 7.1 0.90 0.4 0.9 0.4 1.42 (0.63-3.20) 0.340 1.41 (0.66-3.23) A(G 95 12.6 0.89 0.990 0.590 0.567 1.41 (0.66-3.53) A(D 0.0 0.4 0.0 0.44 0.9 0.567 1.41 (0.66-3.53) 1.37 (0.52-3.50) 1.37 (0.52-3.53) A(D 1.4 1.37 (0.52-3.60)	rs4986832 Allele frequen rs4986832 A/A A/G A/G A/G A/G Allele frequen A/G ALOX5AP rs1132340 A/A ALOX5 rs434473 A/A ALOX12 rs434473 A/G ALOX12 rs434473 A/G ALOX12 rs3892408 C/C ALOX15 rs3892408 C/C	ency 18.7 64.7 32.8 2.6	18.0 60.6 36.0 3.5	4.4				
rs4986832 A/A 647 666 59.8 0.700 1.28 (0.60-2.03) A/G 32.8 35.0 35.7 1.07 (0.63-1.81) 0.300 1.28 (0.80-2.03) A/B A/B 21.5 3.5 0.667 1.18 (0.67-2.09) 0.499 1.41 (0.68-2.91) A/D A/B 90.2 87.0 86.5 0.30 1.42 (0.53-3.20) 0.499 1.41 (0.68-2.91) A/D 0.49 90.5 87.0 86.5 0.30 0.340 1.41 (0.68-2.92) A/D 0.49 0.0 0.4 0.0 1.42 (0.53-3.50) 0.499 1.41 (0.68-2.92) A/D 0.49 0.0 0.4 0.0 0.44 1.41 (0.68-2.92) A/D 0.40 0.4 0.0 0.44 1.41 (0.68-2.92) 1.41 (0.68-2.92) A/D 0.41 3.2 3.21 3.20 0.591 1.42 (0.52-3.60) 1.41 (0.68-2.92) A/D 4.4 3.2 3.21 3.20 0.591 1.37 (0.52-3.60) <td< th=""><th>rs4986832 A/A A/G A/G A/D G/G Allele frequen A/G ALOX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX12 rs41473 A/A ALOX12 rs434473 A/A ALOX12 rs4136667 A/A ALOX12 rs3892408 A/G ALOX15 rs3892408 C/C</th><th>64.7 32.8 2.6</th><th>60.6 36.0 3.5</th><th>21.65</th><th>0.882</th><th>0.94 (0.53–1.68)</th><th>0.588</th><th>1.18 (0.68–2.04)</th></td<>	rs4986832 A/A A/G A/G A/D G/G Allele frequen A/G ALOX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX12 rs41473 A/A ALOX12 rs434473 A/A ALOX12 rs4136667 A/A ALOX12 rs3892408 A/G ALOX15 rs3892408 C/C	64.7 32.8 2.6	60.6 36.0 3.5	21.65	0.882	0.94 (0.53–1.68)	0.588	1.18 (0.68–2.04)
A/G 32.8 36.0 35.7 4.6 32.8 36.0 35.7 4.6 2.6 3.5 4.5 1.31 $2.40,72-2.15$ $2.40,72-2.15$ Allele frequency 9.0 215 $2.2.35$ 0.667 1.18 $0.67-2.09$ 0.499 $1.24(0.72-2.15)$ A/C A/G 9.0 8.5 0.300 1.41 $0.68-2.25$ A/C A/G 9.0 8.5 0.300 1.41 $0.68-2.25$ A/C A/G 0.0 0.64 1.37 $0.23-3.50$ 0.567 1.41 A/C 9.2 3.2	ALOX5AP rs1132340 A/G ALOX5AP rs1132340 A/A ALOX12 rs1132340 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs4126667 A/A ALOX15 rs3892408 C/C ALOX15 rs3892408 C/T	32.8 2.6	36.0 3.5	59.8	0.790	1.07 (0.63–1.81)	0.300	1.28 (0.80–2.03)
6/G 3.5 4.5 4.5 Allele frequency 19.0 21.5 2.235 0.667 1.18 0.499 $1.24(0.72-315)$ Allele frequency 19.0 21.5 2.235 0.667 1.18 0.340 1.41 $0.68-2.92$ Alle $4/G$ 9.5 1.26 0.340 1.42 $0.65-3.200$ 0.49 1.41 $0.68-2.92$ Alle $4/G$ 9.5 1.26 0.340 0.49 1.41 $0.68-3.250$ 1.41 $0.68-2.920$ Alle 1.66 0.25 0.64 0.66 1.42 $0.65-1.66$ 1.24 $0.65-1.85$ Alle 1.64 0.2 0.64 0.66 0.64 1.16 $0.65-1.85$ 1.24 $0.66-1.85$ Alle 1.64 0.7 1.74 0.250 0.250 0.249 1.26 $0.51-1.52$ Alle 1.44 2.07 1.74 0.250 0.849	G/G G/G ALOX5AP rs1132340 A/A ALOX5AP rs1132340 A/A ALOX5AP s1132340 A/G ALOX12 rs434473 A/G ALOX12 rs434473 A/A ALOX12 rs3892408 C/C ALOX15 rs3892408 C/T	26	3.5	35.7				
Mile frequency 10 21.5 0.667 1.18 (0.67-2.09) 0.499 1.24(0.72-2.15) ALOX5AF s1132340 A/A 90.5 87.0 86.5 0.390 1.42 (0.63-3.20) 0.340 141 (0.68-2.91) A/G 9.5 12.6 13.6	Allele frequen ALOX5AP rs1132340 Allele frequen ALOX5AP rs1132340 A/G ALOX5AP rs1132340 A/G ALOX12 rs1132340 A/G ALOX12 rs434473 A/G ALOX12 rs434473 A/G ALOX12 rs434473 A/G ALOX12 rs4126667 A/G rs1126667 A/G A/G ALOX15 rs3892408 C/C ALOX15 rs3892408 C/C	0.1		4.5				
ALOX5AP Ist 132340 A/4 0.5 8.50 0.5390 1.42 0.633-3.20 0.340 1.41 0.68-2.25 A/G 0.5 1.26 13.6 1.36 1.37 0.533-3.50 1.37 0.533-3.53 A/G 0.0 0.4 0.0 0.4 0.0 1.37 0.533-3.50 1.37 0.533-3.53 ALOX72 Fdefrequency 48 6.70 6.80 0.644 1.37 0.523-3.60 1.37 0.53-3.53 ALOX72 F433473 A/A 37.2 32.1 32.0 0.591 1.37 0.52-3.60 1.37 0.53-3.53 ALOX72 F43473 A/A 37.2 32.1 32.0 0.591 1.37 0.52-3.60 1.37 0.56-1.53 1.37 0.55-1.53 1.37 0.55-1.53 1.37 0.55-1.53 1.37 0.56-1.53 1.37 0.56-1.53 1.37 0.56-1.53 1.37 0.56-1.53 1.37 0.56-1.53 1.37 0.56-1.53 1.36 0.57-1.51	ALOX5AP rs1132340 A/A A/G A/G A/D A/Iele frequen ALOX12 rs434473 A/A ALOX12 rs3892408 C/C ALOX15 rs3892408 C/T	ency 19.0	21.5	22.35	0.667	1.18 (0.67–2.09)	0.499	1.24(0.72–2.15)
A/G B/G A/G B/G	A/G G/G G/G G/G ALOX12 rs434473 ALOX12 rs434473 A/G	90.5	87.0	86.5	0.390	1.42 (0.63–3.20)	0.340	1.41 (0.68–2.92)
6/G 0.0 0.4 0.0 $1.37(0.52-3.60)$ 0.653 $1.37(0.53-3.53)$ Allele frequency 4.8 6.70 6.80 0.644 $1.37(0.52-3.60)$ 0.653 $1.37(0.53-3.53)$ ALOX12 re334473 A/A 37.2 32.1 32.0 0.591 $1.16(0.68-1.96)$ 0.550 $1.26(0.85-1.85)$ ALOX12 re34473 A/A 37.2 32.1 32.0 0.591 $1.16(0.68-1.96)$ 0.250 $1.26(0.85-1.85)$ ALOX12 re34473 A/A 31.2 32.1 32.0 0.591 $1.16(0.68-1.96)$ 0.250 $1.26(0.85-1.85)$ ALOX15 A/G 41.1 44.3 20.7 17.4 0.001 0.230 $1.26(0.85-1.82)$ A/G A/A 32.7 32.7 32.7 0.527 $1.13(0.77-1.66)$ 0.849 $10.6(0.62-1.62)$ A/G A/A 32.7 32.7 32.7 32.7 1.27 $1.27(0.84-1.80)$ A/O	G/G ALOX12 rs434473 Allele frequen ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 rs434473 A/A ALOX12 A/A A/G ALOX15 rs3892408 C/C ALOX15 rs3892408 C/T	9.5	12.6	13.6				
Model frequency 4.8 6.70 6.80 0.644 1.37 (0.52-3.60) 0.653 1.37 (0.53-3.53) ALOX12 rs434473 A/A 37.2 32.1 32.0 0.591 1.16 (0.68-1.96) 0.550 1.26 (0.85-1.85) ALOX12 rs434473 A/A 37.2 32.1 32.0 0.591 1.16 (0.68-1.96) 0.250 1.26 (0.85-1.85) A/G 43.5 47.3 50.5 17.4 1.16 (0.68-1.96) 0.250 1.26 (0.85-1.85) G/G 19.4 20.7 17.4 20.7 17.4 1.26 (0.72-1.55) 1.26 (0.72-1.55) A/G A/A 32.5 0.812 1.13 (0.77-1.65) 0.849 1.05 (0.72-1.55) A/G A/A 32.5 0.812 1.07 (0.65-1.83) 0.300 1.23 (0.84-1.80) A/G A/G 19.4 20.4 17.3 2.02 1.07 (0.65-1.83) 0.300 1.04 (0.72-1.51) A/G 19.4 20.4 17.3 2.02 0.621 1.07 (0.65-1.83) 0.380	Allele frequen ALOX12 rs434473 A/A ALOX12 rs434473 A/G ALOX12 s4/3 A/G R A/G A/G R A/Iele frequen A/G R A/Iele frequen A/G R A/Iele frequen A/G ALOX15 rs3892408 C/C ALOX15 rs3892408 C/C	0.0	0.4	0.0				
ALOX12 rs434473 A/A 37.2	ALOX12 rs434473 A/A A/G A/G A/Iele frequen rs1126667 A/A A/G A/G A/G A/G A/G A/G A/G A/G A/C A/G ALOX15 rs3892408 C/T C/T	ency 4.8	6.70	6.80	0.644	1.37 (0.52–3.60)	0.653	1.37 (0.53–3.53)
A/G 4.3 50.5 4.1 4.3 50.5 G/G 19.4 20.7 17.4 1.13 (0.77-1.66) 0.849 1.05 (0.72-1.52) Allel frequency 41.1 44.3 42.6 0.557 1.13 (0.77-1.66) 0.849 1.05 (0.72-1.52) Allel frequency 41.1 44.3 32.5 0.812 1.07 (0.63-1.83) 0.300 1.23 (0.84-1.80) A/G A/G 43.5 42.6 0.812 1.07 (0.63-1.83) 0.300 1.23 (0.84-1.80) A/G 43.5 42.6 0.812 1.07 (0.63-1.83) 0.300 1.23 (0.84-1.80) A/G 43.5 42.6 50.2 17.3 3.20 1.23 (0.84-1.80) A/G 194 20.4 17.3 3.25 0.812 1.07 (0.53-1.63) 0.300 1.04 (0.72-1.51) ALOX15 F 21.6 52.3 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) ALOX15 F 21.7 21.6 21.0001 pc = 0.00	A/G G/G Allele frequen rs1126667 A/A A/G G/G G/G ALOX15 rs3892408 C/C	37.2	32.1	32.0	0.591	1.16 (0.68–1.96)	0.250	1.26 (0.85–1.85)
6/G 19.4 20.7 17.4 Allele frequency 11.1 44.3 42.6 0.557 1.13 0.249 1.05 $0.24-1.52$ rs1126657 A/A 37.2 32.5 0.812 1.07 $0.63-1.83$ 0.300 1.23 $0.84-1.80$ A/G 37.2 32.5 0.812 1.07 $0.63-1.83$ 0.300 1.23 $0.84-1.80$ A/G 43.5 46.9 50.2 0.812 1.07 0.300 1.23 $0.84-1.80$ A/G 43.5 32.5 0.812 1.07 $0.53-1.83$ 0.300 1.23 $0.84-1.80$ A/G 194 20.4 17.3 0.812 0.300 1.23 $0.84-1.80$ A/G 173 32.9 $0.630-1.83$ 0.300 $0.84-1.80$ 1.04 0.23 $AIOXIS$ ISS 20.4 17.3 0.001 0.2001 1.24 $0.26-5.62$ 0.100	G/G Allele frequen rs1126667 A/A A/G G/G G/G ALOX15 rs3892408 C/C C/T	43.5	47.3	50.5				
Allele frequency 4.1 4.4.3 4.2.6 0.557 1.13 (0.77-1.66) 0.849 1.05 (0.72-1.52) rs1126657 A/A 37.2 32.7 32.5 0.812 $1.07 (0.63-1.83)$ 0.300 $1.23 (0.84-1.80)$ A/G 43.5 46.9 50.2 $1.07 (0.63-1.83)$ 0.300 $1.23 (0.84-1.80)$ A/G 43.5 46.9 50.2 $1.07 (0.63-1.83)$ 0.300 $1.23 (0.84-1.80)$ A/G 43.5 46.9 50.2 $1.07 (0.65-1.63)$ 0.300 $1.23 (0.84-1.80)$ A/G 19.4 20.4 17.3 20.6 $1.02 (0.50-1.63)$ 0.300 $1.04 (0.72-1.51)$ ALOX15 rs3892408 C/C 54.4 20.6 $0.0001 pc = 0.0011$ $3.29 (1.93-5.60)$ $0.0001 pc = 0.0011$ $3.48 (2.08-5.80)$ ALOX15 rs3892408 C/C 31.6 22.3 52.6 $0.0001 pc = 0.0011$ $3.29 (1.93-5.60)$ $0.0001 pc = 0.0011$ T/T 14.0 19.9 21.5 <t< th=""><th>Allele frequen rs1126667 A/A A/G G/G G/G ALOX15 rs3892408 C/C C/T</th><th>19.4</th><th>20.7</th><th>17.4</th><th></th><th></th><th></th><th></th></t<>	Allele frequen rs1126667 A/A A/G G/G G/G ALOX15 rs3892408 C/C C/T	19.4	20.7	17.4				
rs112667 A/A 37.2 32.5 0.812 $1.07(0.63-1.83)$ 0.300 $1.23(0.84-1.80)$ A/G 43.5 46.9 50.2 1.04 0.300 $1.23(0.84-1.80)$ G/G 43.5 46.9 50.2 1.04 0.621 $1.07(0.53-1.63)$ 0.350 $1.04(0.72-1.51)$ Allole frequency 41.1 43.8 22.9 $0.0001 \text{ pc} = 0.0011$ $3.29(1.93-5.60)$ $0.0001 \text{ pc} = 0.0011$ $3.48(2.08-5.80)$ ALOX15 rs3892408 C/C 54.4 27.8 25.9 $0.0001 \text{ pc} = 0.0011$ $3.29(1.93-5.60)$ $0.0001 \text{ pc} = 0.0011$ $3.48(2.08-5.80)$ ALOX15 rs3892408 C/C 54.4 27.8 25.6 $0.0001 \text{ pc} = 0.0011$ $3.29(1.93-5.60)$ $0.0001 \text{ pc} = 0.0011$ $3.48(2.08-5.80)$ T/T 14.0 19.9 27.8 25.6 $1.04(0.72-1.61)$ $1.04(0.52-1.62)$ T/T 14.0 19.9 21.5 21.8 21.7 21.8 21.8 21.8	rs1126667 A/A A/G G/G ALOX15 rs3892408 C/C C/T	ency 41.1	44.3	42.6	0.557	1.13 (0.77–1.66)	0.849	1.05 (0.72–1.52)
A/G 43.5 46.9 50.2 G/G 19.4 20.4 17.3 0.850 1.04 (0.75-1.63) 0.850 1.04 (0.72-1.51) Allele frequency 41.1 43.8 42.4 0.621 1.10 (0.75-1.63) 0.850 1.04 (0.72-1.51) ALOX15 r53892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) ALOX15 r53892408 C/C 31.6 52.3 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) ALOX15 r53892408 C/C 31.6 52.3 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) T/T 14.0 19.9 21.5 21.6 0.0001 pc = 0.0011 2.48 (2.08-5.80) Allele frequency 19.9 21.5 0.0001 pc = 0.0011 1.83 (1.38-2.43) 0.0001 pc = 0.0011 2.06 (1.52-2.62) results Allele frequency 21.7 7.1 0.106 (0.60-1.87) 0	A/G G/G ALOX15 rs3892408 C/C C/T	37.2	32.7	32.5	0.812	1.07 (0.63–1.83)	0.300	1.23 (0.84–1.80)
G/G 19.4 20.4 17.3 Allele frequency 41.1 43.8 20.4 17.3 0.850 1.04 (0.75-1.51) ALOX15 rs3892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) ALOX15 rs3892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) ALOX15 rs3892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) C/T 31.6 52.3 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) T/T T/T 14.0 19.9 21.5 19.8 0.0001 pc = 0.0011 2.06 (1.93-5.43) 0.0001 pc = 0.0011 2.06 (1.52-2.62) Allele frequency 29.8 46.0 71.7 71.7 0.880 1.04 (0.63-1.71)	G/G ALOX15 rs3892408 C/C C/T	43.5	46.9	50.2				
Allele frequency 41.1 43.8 42.4 0.621 1.10 (0.75-1.63) 0.850 1.04 (0.72-1.51) ALOX15 rs3892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) ALOX15 rs3892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) C/T 31.6 52.3 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) T/T 14.0 19.9 21.5 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.63) 0.0001 pc = 0.0011 2.48 (2.08-5.80) Allele frequency 29.8 46.0 47.8 0.0001 pc = 0.0011 1.83 (1.38-2.43) 0.0001 pc = 0.0011 2.00 (1.52-2.62) rs11568131 A/A 71.7 73.1 71.7 0.840 1.06 (0.60-1.87) 0.880 1.04 (0.63-1.71)	Allele frequen ALOX15 rs3892408 C/C C/T	19.4	20.4	17.3				
ALOX75 rs3892408 C/C 54.4 27.8 25.9 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) C/T 31.6 52.3 52.6 0.0001 pc = 0.0011 3.29 (1.93-5.60) 0.0001 pc = 0.0011 3.48 (2.08-5.80) T/T 31.6 52.3 52.6 21.5 21.5 21.5 21.5 Allele frequency 29.8 46.0 47.8 0.0001 pc = 0.0011 1.83 (1.38-2.43) 0.0001 pc = 0.0011 2.00 (1.52-2.62) rs11568131 A/A 71.7 73.1 71.7 0.840 1.06 (0.60-1.87) 0.880 1.04 (0.63-1.71)	ALOX15 rs3892408 C/C C/T	ency 41.1	43.8	42.4	0.621	1.10 (0.75–1.63)	0.850	1.04 (0.72–1.51)
C/T 31.6 52.3 52.6 T/T 14.0 19.9 21.5 Allele frequency 29.8 46.0 47.8 0.0001 pc = 0.0011 1.83 (1.38–2.43) 0.0001 pc = 0.0011 2.00 (1.52–2.62) rs11568131 A/A 71.7 73.1 71.7 0.840 1.06 (0.60–1.87) 0.880 1.04 (0.63–1.71)	C/T	54.4	27.8	25.9	0.0001 pc = 0.0011	3.29 (1.93–5.60)	0.0001 pc = 0.0011	3.48 (2.08–5.80)
T/T 14.0 19.9 21.5 Allele frequency 29.8 46.0 47.8 0.0001 pc = 0.0011 1.83 (1.38–2.43) 0.0001 pc = 0.0011 2.00 (1.52–2.62) rs11568131 A/A 71.7 73.1 71.7 0.840 1.06 (0.60–1.87) 0.880 1.04 (0.63–1.71)		31.6	52.3	52.6				
Allele frequency 29.8 46.0 47.8 0.0001 pc = 0.0011 1.83 (1.38-2.43) 0.0001 pc = 0.0011 2.00 (1.52-2.62) rs11568131 A/A 71.7 73.1 71.7 0.840 1.06 (0.60-1.87) 0.880 1.04 (0.63-1.71)	Т/Т	14.0	19.9	21.5				
rs11568131 A/A 71.7 73.1 71.7 0.840 1.06 (0.60–1.87) 0.880 1.04 (0.63–1.71)	Allele frequen	ency 29.8	46.0	47.8	0.0001 pc = 0.0011	1.83 (1.38–2.43)	0.0001 pc = 0.0011	2.00 (1.52–2.62)
	rs11568131 A/A	71.7	73.1	71.7	0.840	1.06 (0.60–1.87)	0.880	1.04 (0.63–1.71)

Research Article Ayuso, Plaza-Serón, Blanca-López et al.

Gene NPD MED NTO MED NED NED </th <th>Table 2. d</th> <th>Genotype and</th> <th>minor allele freque</th> <th>incies of t</th> <th>he SNPs i</th> <th>n arachidor</th> <th>nic acid pathway ger</th> <th>ies (cont.).</th> <th></th> <th></th>	Table 2. d	Genotype and	minor allele freque	incies of t	he SNPs i	n arachidor	nic acid pathway ger	ies (cont.).		
ALONDE ST15813 Actionational OR (95% CI) posulue OR (95% CI) posulue OR (95% CI) (con1) G/G 25 12 24 15 12 24 (con1) G/G 25 12 13 161 0.26 102 (0.56-1.87) 0.980 102 (0.56-1.85) Pr051 S15 13 161 133 161 0.36 102 (0.56-1.87) 0.980 103 (0.00-0.03) Pr051 CC 33 183 0.7 0.0001 pc = 0.0011 0.10 (0.00-0.03) 0.10 (0.00-0.03) Allel Frequency 35 961 96.7 0.400 0.38 (0.19-3.46) 0.10 (0.00-0.03) Allel Frequency 25 91 0.35 0.44 0.38 (0.40-1.50) 0.74 (0.24-2.33) Allel Frequency 21 195 0.460 0.38 (0.40-1.50) 0.74 (0.24-2.33) Allel Frequency 23 13 0.33 0.32 0.38 (0.40-1.50) 0.36 (0.40-1.50) 0.36 (0.40-1.50) 0.36 (0.40-1.50) 0.44 (0.42-1.50	Gene	SNP	Genotype	NERD	NTA	Controls	NERD	vs NTA	NERD vs	controls
ALOXIS StillsBill AGC 25 2.3 2.4 3.3 0.3 Fricti GG 5 1.7 4.0 0.9001 qc=1.67) 0.980 102 (0.54-1.87) Fricti Sig 5.7 5.5 2.3 81.0 0.750 0.9001 qc=0.0011 0.01 (0.00-0.003) Fricti C/C 5.3 81.0 0.3 0.0001 pc=0.0011 0.01 (0.00-0.003) Alm Alm 33 0.0 0.0001 pc=0.0011 0.33 (0.22-0.48) 0.001 (0.00-0.003) Alm 6/G 9.5 9.1 0.00 0.28 (0.16-3.94) 0.001 (pc=0.0011 Alm 6/G 9.5 9.1 0.20 0.3 0.001 (pc=0.011 0.10 (0.00-0.03) Alm 6/G 9.5 9.1 0.70 0.33 (0.22-0.48) 0.74 (0.24-2.33) Alm Alm 0.0 0.0 0.0 0.0001 pc=0.011 0.34 (0.24-2.33) Alm Alm 0.0 0.0 0.0001 pc=0.0101 0.33 (0.22-0.48) 0.01 (0.0-0.02) <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>p-value</th> <th>OR (95% CI)</th> <th>p-value</th> <th>OR (95% CI)</th>							p-value	OR (95% CI)	p-value	OR (95% CI)
(cont.) G_{1G} 2.6 1.7 4.0 1.02 0.56 1.2 0.200 0.000 1.02 0.56 1.02 0.56 1.02 0.56 0.000	ALOX15	rs11568131	A/G	25.7	25.2	24.3				
Mile frequency 15,4 14,3 16,1 0.700 pc.800 0.980 102 0.56-1.87) 0.980 102 0.56-1.87) 0.12 0.56-1.87) 0.12 0.56-1.87) 0.12 0.56-1.87) 0.12 0.56-1.87) 0.12 0.56-1.87) 0.12 0.56-1.87) 0.12 0.56-1.87) 0.12 0.12 0.13 <th0.13< th=""> 0.13 <th0.13< th=""> <th< th=""><th>(cont.)</th><th>(cont.)</th><th>G/G</th><th>2.6</th><th>1.7</th><th>4.0</th><th></th><th></th><th></th><th></th></th<></th0.13<></th0.13<>	(cont.)	(cont.)	G/G	2.6	1.7	4.0				
FYG51 C/C 35 81/1 900 00001 0.28(018-0.44) 0.00011 0.01010 0.0011 0.01010 0.0011 0.01010 0.0011 0.000111 0.000111 0.000111 0.000111 0.000111 0.000111 0.000111 0.000111 0.000111 0.000111 0.01010000000 0.00010000000 0.00010000000 0.000100000000000000000000000000000000			Allele frequency	15.4	14.3	16.1	0.750	0.90 (0.48–1.67)	0.980	1.02 (0.56–1.85)
CA 43.0 18.3 0.7 A/A 3.5 0.0 0.0 A/A 3.5 0.0 0.0 Allele frequency 5.5 9.1 6.5 0.23(0.22-0.48) 0.6001 pc = 0.0011 0.14(0.00-0.05) A/A 6/A 4.3 3.9 3.3 0.0001 pc = 0.0011 0.31(0.02-0.48) 0.60 0.74(0.24-2.3) A/A 0.0 0.0 0.0 0.0 0.0 0.0 0.74(0.24-2.34) 0.69(0.16-2.6) 0.74(0.24-2.34) A/A 0.0 0.0 0.0 0.0 0.0 0.74(0.24-2.34) 0.69(0.16-2.6) 0.50(0.16-2.6)	PTGS1	rs5789	C/C	53.5	81.7	99.3	0.0001 pc = 0.0011	0.28 (0.18–0.44)	0.0001 pc = 0.0011	0.01 (0.00–0.03)
A/A 35 0.0 0.0 0.0 Allele frequency 55.0 91 0.35 0.001 pc = 0.011 0.31 (0.20-0.48) 0.0001 pc = 0.001 0.74 (0.24-2.33) Allele frequency 55.0 95.1 95.7 0.51 1.25 (0.33-4.65) 0.610 0.74 (0.24-2.33) A/A 0.0 0.0 0.0 0.0 0.0 0.0 0.74 (0.24-2.33) 0.593 0.51 0.74 (0.24-2.33) A/A Alle frequency 2.15 1.95 1.65 0.73 (0.40-1.50) 0.74 (0.24-2.33) 0.590 (15) A/A 0.0 0.0 0.0 0.0 0.0 0.0 0.94 (1.01-2.30) 0.590 (15) 0.500 (15) A/A 0.0 0.0 0.0 0.0 0.0 0.0 0.94 (1.01-1.80) 0.590 (15) A/A A/A 1.91 1.91 0.780 (1.40-1.80) 0.660 0.99 (1.52-2.83) A/A Allele frequency 2.11 1.9 0.780 (1.40-1.80) 0.500 (15) 0.500 (15) F10			C/A	43.0	18.3	0.7				
Allels frequency 5:0 9:1 0.35 0.0001 0.33 0.22-0.43 0.0001 0.			A/A	3.5	0.0	0.0				
15734 $G(G)$ 9.7 9.61 9.67 0.740 $1.25(0.33 - 4.66)$ 0.610 $0.74(0.24 - 2.33)$ A/A 0.0 0.0 0.0 0.0 0.0 0.0 $0.74(0.24 - 2.33)$ A/A 0.0 0.0 0.0 0.0 0.0 0.0 0.00			Allele frequency	25.0	9.1	0.35	0.0001 pc = 0.0011	0.33 (0.22–0.48)	0.0001 pc = 0.0011	0.01 (0.00–0.05)
6/A 6.3 3.3 <t< th=""><th></th><th>rs5794</th><th>G/G</th><th>95.7</th><th>96.1</th><th>96.7</th><th>0.740</th><th>1.25 (0.33–4.66)</th><th>0.610</th><th>0.74 (0.24–2.33)</th></t<>		rs5794	G/G	95.7	96.1	96.7	0.740	1.25 (0.33–4.66)	0.610	0.74 (0.24–2.33)
A/A 0.0 <th></th> <th></th> <th>G/A</th> <th>4.3</th> <th>3.9</th> <th>3.3</th> <th></th> <th></th> <th></th> <th></th>			G/A	4.3	3.9	3.3				
Allel frequency 2.15 1.65 0.722 0.81 0.193.48) 0.699 0.690 <th></th> <th></th> <th>A/A</th> <th>0.0</th> <th>0.0</th> <th>0.0</th> <th></th> <th></th> <th></th> <th></th>			A/A	0.0	0.0	0.0				
rs123613 G/G 95.7 96.1 0.67 0.78 (0.40-1.50) 0.720 0.90 (0.50-1.61) G/A 0.0 0.0 0.0 0.0 0.0 0.0 0.93 (0.42-1.89) 0.846 0.89 (0.42-1.89) A/A 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.93 (0.42-1.89) 0.846 0.89 (0.42-1.89) 0.846 0.89 (0.42-1.89) 0.846 0.89 (0.42-1.89) 0.84 0.89 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.29 (0.42-1.80) 0.81 (0.42-1.89) 0.84 0.89 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 0.81 (0.42-1.89) 0.84 (0.43-1.80) 0.84 (0.43-1.80) 0.84 0.81 (0.42-1.80) 0.84			Allele frequency	2.15	1.95	1.65	0.722	0.81 (0.19–3.48)	0.699	0.69 (0.16–2.96)
G/A 4.3 3.9 3.3 A/A 0.0		rs1236913	G/G	95.7	96.1	96.7	0.460	0.78 (0.40–1.50)	0.720	0.90 (0.50–1.61)
A/A 0.0 0.0 0.0 0.0 0.0 Hele frequency 2.1 1.9 1.6 0.841 0.846 0.89 (0.42-1.89) r/A Allele frequency 2.1 1.9 1.6 0.841 0.662 1.21 (0.52-2.83) r/C 7/C 7.0 11.7 8.3 91.4 0.066 1.90 (0.94-3.84) 0.662 1.21 (0.52-2.83) r/C 7.0 11.7 8.3 91.4 0.066 1.90 (0.94-3.84) 0.662 1.21 (0.52-2.83) r/C 7.0 11.7 8.3 91.4 0.066 1.90 (0.94-3.84) 0.662 1.21 (0.52-2.83) r/C 7.0 11.7 8.3 0.45 0.04 0.846 0.89 (0.43-4.53) r/C 0.0 0.5 0.4 0.041 1.91 (1.01-3.60) 0.257 1.36 (0.43-4.23) r/C 71 1.13 8.6 0.013 pc = 0.049 0.703 r.4.243) 1.36 (0.47-1.36) 1.36 (0.71-3.43) r/T 1.13 1.91 (1.01-3.61)			G/A	4.3	3.9	3.3				
Allele frequency 1 1.9 1.6 0.841 0.846 0.89 $0.42-1.89$ rs10306108 17 93.0 87.8 91.4 0.066 1.20 0.39 0.39 0.32 0.39 $0.42-1.89$ $7/C$ $7/O$ 11.7 8.3 91.4 0.066 1.20 0.52 1.21 $0.52-2.83$ $7/C$ $7/O$ 11.7 8.3 0.45 0.257 1.78 0.662 1.21 $0.25-2.83$ Allele frequency 3.5 6.35 0.47 0.041 1.91 1.90 0.220 1.21 1.21 0.220 1.21 0.230 1.21 0.230 1.21 0.230 1.57 0.271 0.29 0.271 1.21 0.230 1.27 0.271 0.29 0.271 0.29 0.271 0.29 0.271 0.29 0.271 0.271 0.271 0.271 0.272 0.271 0.271			A/A	0.0	0.0	0.0				
rs10306108 $1/7$ 9:0 87.8 91.4 0.066 1.90 (0.94-3.84) 0.662 1.21 (0.52-2.83) $7/C$ 70 11.7 8.3 $$			Allele frequency	2.1	1.9	1.6	0.841	0.87 (0.40–1.89)	0.846	0.89 (0.42–1.89)
T/C 70 11.7 8.3 C/C 0.0 0.5 0.4 Allele frequency 3.5 6.35 4.55 0.257 1.78(0.69-4.56) 0.787 1.56(0.43-4.23) rs3842787 C/C 0.0 0.5 0.4 1.71(101-3.60) 0.220 1.67(0.71-3.89) rs3842787 C/C 2.10 11.3 8.6 1.91(1.01-3.60) 0.220 1.67(0.71-3.89) rs3842787 C/C 2.10 11.3 8.6 0.041 pc = 0.144 1.91(1.01-3.60) 0.220 1.67(0.71-3.89) rs13842787 C/C 32 0.31 2.12(1.12-3.60) 0.220 1.67(0.71-3.89) rs13842787 C/C 0.9 2.8 0.00 1.20(1.31-3.60) 0.220 1.67(0.71-3.89) r<17 Allele frequency 8.4 4.3 0.013 pc = 0.069 2.12(1.17-3.83) 0.192 1.99(0.73-5.45) r<17030135 A/A 8.3 0.0 0.0009 pc = 0.0091 2.19(1.13-2.32) 0.0064 pc = 0.045 1.67(0.12-2.43) <tr< th=""><th></th><th>rs10306108</th><th>Т/Т</th><th>93.0</th><th>87.8</th><th>91.4</th><th>0.066</th><th>1.90 (0.94–3.84)</th><th>0.662</th><th>1.21 (0.52–2.83)</th></tr<>		rs10306108	Т/Т	93.0	87.8	91.4	0.066	1.90 (0.94–3.84)	0.662	1.21 (0.52–2.83)
C/C 0.0 0.5 0.4 Allele frequency 3.5 6.35 4.55 0.257 1.78 (0.69-4.56) 0.787 1.67 (0.71-3.89) Allele frequency 3.5 6.35 4.55 0.041 pc = 0.144 1.91 (1.01-3.60) 0.220 167 (0.71-3.89) C/T 7.1 11.3 8.6 1.38 0.041 pc = 0.144 1.91 (1.01-3.60) 0.220 167 (0.71-3.89) T/T 7.1 11.3 8.6 0.041 pc = 0.144 1.91 (1.01-3.60) 0.220 1.67 (0.71-3.89) T/T 7.1 11.3 8.6 0.00 2.8 0.013 pc = 0.049 1.91 (1.01-3.60) 0.220 1.67 (0.71-3.89) Allel frequency 8.4 8.3 0.0 2.8 0.0 2.8 0.013 pc = 0.0091 2.12 (1.17-3.83) 0.192 (1.37-3.45) A/T 12.2 28.9 2.73 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) T/T 117.8 16.85 0.0080 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045			T/C	7.0	11.7	8.3				
Allele frequency 3.5 6.35 4.55 0.257 $1.78(0.69-4.56)$ 0.787 $1.56(0.43-4.23)$ rs384787 C/C 92.0 85.9 91.4 $0.041 pc = 0.144$ $1.91(1.01-3.60)$ 0.220 $1.67(0.71-3.89)$ C/T 7.1 11.3 8.6 2.2 $0.041 pc = 0.144$ $1.91(1.01-3.60)$ 0.220 $1.67(0.71-3.89)$ T/T 7.7 11.3 8.6 0.0 $0.013 pc = 0.069$ $2.12(1.17-3.83)$ 0.192 $1.67(0.71-3.89)$ T/T 0.9 2.8 0.0 $0.013 pc = 0.069$ $2.12(1.17-3.83)$ 0.192 $1.99(0.73-5.45)$ Allele frequency 8.4 8.3 $0.013 pc = 0.069$ $2.12(1.17-3.83)$ 0.192 $0.72(0.71-3.89)$ A/T 8.4 8.4 $0.003 pc = 0.0069$ $2.12(1.17-3.83)$ $0.192(0.73-5.45)$ $1.99(0.73-5.45)$ A/T 12.2 2.12 $0.003 pc = 0.0069$ $2.19(1.37-3.52)$ $0.0064 pc = 0.045$ $1.2(1.12-3.43)$ T/T 4.3			C/C	0.0	0.5	0.4				
rs3842787 C/C 92.0 85.9 91.4 $0.041 \text{ pc} = 0.144$ $1.91 (1.01 - 3.60)$ 0.220 $1.67 (0.71 - 3.89)$ C/T 7.1 11.3 8.6 1.13 8.6 1.67 (0.71 - 3.89) T/T 0.9 2.8 0.0 2.8 0.013 pc = 0.069 2.12 (1.17 - 3.83) $1.67 (0.71 - 3.89)$ Allele frequency 4.4 8.4 4.3 0.013 pc = 0.069 2.12 (1.17 - 3.83) 0.192 $1.99 (0.73 - 5.45)$ Allele frequency 4.4 8.4 4.3 0.0009 pc = 0.0091 2.19 (1.37 - 3.52) $0.0064 \text{ pc} = 0.045$ 2.12 (1.21 - 3.45) A/T 12.2 28.9 27.3 $0.0009 \text{ pc} = 0.0091$ 2.19 (1.37 - 3.52) $0.0064 \text{ pc} = 0.045$ $2.12 (1.21 - 3.45)$ A/T 12.2 28.9 27.3 $2.13 (1.15 - 2.59)$ $0.0064 \text{ pc} = 0.045$ $2.12 (1.21 - 3.74)$ T/T 4.3 3.4 3.2 $2.73 (1.15 - 2.59)$ $0.0064 \text{ pc} = 0.045$ $1.5 (1.12 - 2.43)$ Prices 1 17 4.3 3.4 3.2			Allele frequency	3.5	6.35	4.55	0.257	1.78 (0.69–4.56)	0.787	1.36 (0.43–4.23)
C/T 7.1 11.3 8.6 T/T 0.9 2.8 0.0 Allele frequency 4.4 8.4 4.3 0.013 pc = 0.069 2.12 (1.17-3.83) 0.192 1.99 (0.73-5.45) rs10306135 A/A 8.5 67.7 69.4 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 0.0008 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 0.0008 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) T/T 4.3 3.4 3.2 3.4 3.2 3.1 3.1 3.1 1.55 (1.21-3.74) FIGE frequency 12.2 28.9 3.4 3.2 0.0080 pc = 0.0069 0.137 (0.44-1.35) 0.0081 pc = 0.046 1.65 (1.12-2.43) FIGE frequency 15.4		rs3842787	C/C	92.0	85.9	91.4	0.041 pc = 0.144	1.91 (1.01–3.60)	0.220	1.67 (0.71–3.89)
T/T 0.9 2.8 0.0 Allele frequency 4.4 8.4 4.3 0.013 pc = 0.069 2.12 (1.17-3.83) 0.192 1.99 (0.73-5.45) rs10306135 A/A 83.5 67.7 69.4 0.0009 pc = 0.0691 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 3.4 3.2 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 3.4 3.2 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.8 17.6 1.65 (1.12-2.43) 0.10081 pc = 0.046 1.65 (1.12-2.43) PTGS2 rs689465 T/T 65.7 69.0 66.4 0.370 0.77 (0.44-1.35) 0.94 (0.58-1.52) T/C 3.6 2.72 2.91 0.370 0.77 (0.44-1.35)			C/T	7.1	11.3	8.6				
Allele frequency 4.4 8.4 4.3 0.013 pc = 0.069 2.12 (1.17-3.83) 0.192 1.99 (0.73-5.45) rs10306135 A/A 83.5 67.7 69.4 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 0.0009 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 0.0008 pc = 0.0091 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) A/T 12.2 28.9 27.3 3.4 3.2 2.19 (1.37-3.52) 0.0064 pc = 0.045 2.12 (1.21-3.74) Alter trapuercy 10.4 17.8 16.85 0.0080 pc = 0.046 1.73 (1.15-2.59) 0.0081 pc = 0.046 1.65 (1.12-2.43) PTGS2 rs689465 7/T 69.0 66.4 0.370 0.77 (0.44-1.35) 0.94 (0.58-1.52) PTGS2 rs689465 7/T 63.0 23.7 3.8 4.4 PTGS2 3.7 3.8 4.4			Т/Т	0.9	2.8	0.0				
rs10306135 A/A 83.5 67.7 69.4 $0.0009 \text{ pc} = 0.0091$ $2.19 (1.37 - 3.52)$ $0.0064 \text{ pc} = 0.045$ $2.12 (1.21 - 3.74)$ A/T 12.2 28.9 27.3 2.12 2.12 2.12 2.12 T/T 12.2 28.9 27.3 3.4 3.2 2.12 $2.12 (1.21 - 3.74)$ T/T 4.3 3.4 3.2 3.2 $0.0080 \text{ pc} = 0.046$ $1.73 (1.15 - 2.59)$ $0.0081 \text{ pc} = 0.046$ $1.65 (1.12 - 2.43)$ PTGS2 rs689465 T/T 65.7 69.0 66.4 0.370 $0.77 (0.44 - 1.35)$ $0.94 (0.58 - 1.52)$ PTGS2 rs689465 T/T 30.6 27.2 29.1 $0.77 (0.44 - 1.35)$ $0.94 (0.58 - 1.52)$ C/C 3.7 3.8 4.4 0.370 $0.77 (0.44 - 1.35)$ $0.94 (0.58 - 1.52)$			Allele frequency	4.4	8.4	4.3	0.013 pc = 0.069	2.12 (1.17–3.83)	0.192	1.99 (0.73–5.45)
A/T 12.2 28.9 27.3 T/T 4.3 3.4 3.2 Allele frequency 10.4 17.8 16.85 0.0080 pc = 0.046 1.73 (1.15-2.59) 0.0081 pc = 0.046 1.65 (1.12-2.43) PTGS2 rs689465 T/T 65.7 69.0 66.4 0.370 0.77 (0.44-1.35) 0.902 0.94 (0.58-1.52) T/C 30.6 27.2 29.1 0.77 (0.44-1.35) 0.802 0.94 (0.58-1.52) C/C 3.7 3.8 4.4		rs10306135	A/A	83.5	67.7	69.4	0.0009 pc = 0.0091	2.19 (1.37–3.52)	0.0064 pc = 0.045	2.12 (1.21–3.74)
T/T 4.3 3.4 3.2 Allele frequency 10.4 17.8 16.85 0.0080 pc = 0.046 1.73 (1.15-2.59) 0.0081 pc = 0.046 1.65 (1.12-2.43) PTGS2 rs689465 T/T 65.7 69.0 66.4 0.370 0.77 (0.44-1.35) 0.94 (0.58-1.52) T/C 30.6 27.2 29.1 C/C 3.7 3.8 4.4			A/T	12.2	28.9	27.3				
Allele frequency 10.4 17.8 16.85 0.0080 pc = 0.046 1.73 (1.15-2.59) 0.0081 pc = 0.046 1.65 (1.12-2.43) PTGS2 rs689465 T/T 65.7 69.0 66.4 0.370 0.77 (0.44-1.35) 0.802 0.94 (0.58-1.52) T/C 30.6 27.2 29.1 29.1 0.77 (0.44-1.35) 0.802 0.94 (0.58-1.52) C/C 3.7 3.8 4.4			Т/Т	4.3	3.4	3.2				
PTGS2 rs689465 T/T 65.7 69.0 66.4 0.370 0.77 (0.44–1.35) 0.802 0.94 (0.58–1.52) T/C 30.6 27.2 29.1 0.94 (0.58–1.52) 0.802 0.94 (0.58–1.52) C/C 3.7 3.8 4.4 0.77 (0.44–1.35) 0.802 0.94 (0.58–1.52)			Allele frequency	10.4	17.8	16.85	0.0080 pc = 0.046	1.73 (1.15–2.59)	0.0081 pc = 0.046	1.65 (1.12–2.43)
T/C 30.6 27.2 29.1 C/C 3.7 3.8 4.4	PTGS2	rs689465	Т/Т	65.7	69.0	66.4	0.370	0.77 (0.44–1.35)	0.802	0.94 (0.58–1.52)
C/C 3.7 3.8 4.4			T/C	30.6	27.2	29.1				
			C/C	3.7	3.8	4.4				

Table 2. 0	Genotype and	minor allele freque	ncies of t	he SNPs i	n arachidor	nic acid pathw	ay genes (cont.).		
Gene	SNP	Genotype	NERD	NTA	Controls		NERD vs NTA	NERD vs	controls
						p-value	OR (95% CI)	p-value	OR (95% CI)
PTGS2 (cont.)	rs689465 (cont.)	Allele frequency	19.0	17.4	18.9	0.648	0.87 (0.48–1.58)	0.960	0.98 (0.56–1.73)
	rs689466	Т/Т	0.69	66.1	6.99	0.861	1.05 (0.62–1.78)	0.930	1.02 (0.63–1.65)
		T/C	29.3	30.5	30.5				
		C/C	1.7	3.4	2.6				
		Allele frequency	16.3	18.6	17.8	0.876	0.96 (0.52–1.77)	0.771	1.12 (0.63–2.01)
CYSLTR1	rs320995	A/A	59.1	68.8	74.4	0.110	0.66 (0.39–1.10)	0.0039 pc = 0.030	0.50 (0.31–0.80)
		A/G	31.3	21.6	16.9				
		G/G	9.6	9.5	8.8				
		Allele frequency	25.2	20.3	17.2	0.335	0.76 (0.45–1.29)	0.0135 pc = 0.069	0.66 (0.48–0.91)
	rs2806489	Т/Т	60.2	57.5	64.9	0.552	1.39 (0.47–4.08)	0.491	0.85 (0.53–1.35)
		T/C	30.1	25.0	22.9				
		C/C	9.7	17.5	12.2				
		Allele frequency	24.7	30.0	23.6	0.795	0.94 (0.56–1.56)	0.800	0.93 (0.57–1.53)
CYSLTR2	rs912278	A/A	26.1	29.9	28.8	0.571	0.85 (0.48–1.49)	0.610	0.88 (0.53–1.45)
		A/G	56.5	50.4	50.5				
		D/D	17.4	19.7	20.7				
		Allele frequency	45.6	44.9	45.9	0.909	0.95 (0.61–1.49)	0.980	1.00 (0.65–1.55)
LTC4S	rs730012	A/A	46.1	51.9	59.0	0.173	0.71 (0.43–1.17)	0.025 pc = 0.107	0.60 (0.38–0.94)
		A/C	43.5	41.5	36.3				
		C/C	10.4	6.6	4.8				
		Allele frequency	32.1	27.3	22.9	0.382	0.79 (0.49–1.29)	0.0156 pc = 0.080	0.69 (0.52–0.93)
PTDGR	rs8004654	C/C	35.6	28.3	23.8	0.681	1.15 (0.59–2.25)	0.021	1.77 (1.09–2.88)
		C/T	44.4	55.7	54.2				
		T/T	20.0	16.0	22.0				
		Allele frequency	42.2	43.8	49.1	0.909	1.05 (0.67–1.65)	0.266	1.30 (0.84–2.01)
	rs34236606	C/C	87.9	84.8	85.9	0.510	1.29 (0.60–2.75)	0.680	1.15 (0.59–2.25)
		C/T	12.1	15.2	13.7				
		T/T	0.0	0.0	0.4				
		Allele frequency	6.05	7.6	7.25	0.659	1.32 (0.53–3.29)	0.828	1.25 (0.51–3.03)
Allele frequer NERD: NSAID	ncy represents the m)s-exacerbated respi	ninor allele frequency for ea ratory disease; NS: Not sign	ch SNP. ificant; NTA	: NSAID-toler	ant asthmatic p	atients; OR: Odds r	atio.		

Research Article Ayuso, Plaza-Serón, Blanca-López et al.

Table 2.	Genotype and	minor allele freque	ncies of t	he SNPs i	n arachidor	nic acid pathway ge	nes (cont.).		
Gene	SNP	Genotype	NERD	NTA	Controls	NERD	vs NTA	NERD vs	controls
						p-value	OR (95% CI)	p-value	OR (95% CI)
PTGER1	rs3810253	A/A	60.9	67.2	74.5	0.642	0.88 (0.52–1.49)	0.0038 pc = 0.030	0.49 (0.28–0.74)
		A/C	37.4	29.3	22.9				
		C/C	1.7	3.5	2.6				
		Allele frequency	20.4	18.1	16.0	0.565	0.85 (0.49–1.49)	0.0012 pc = 0.011	0.57 (0.41–0.80)
	rs3810255	C/C	77.4	77.2	86.0	0.831	0.94 (0.52–1.70)	0.05	0.56 (0.32–0.99)
		C/T	22.6	22.4	13.6				
		Т/Т	0.0	0.4	0.4				
		Allele frequency	11.3	11.6	7.2	0.960	1.05 (0.52–2.11)	0.0009 pc = 0.010	0.48 (0.31–0.73)
PTGER2	rs17197	A/A	79.3	76.7	73.9	0.840	1.06 (0.58–1.94)	0.215	1.41 (0.82–2.41)
		A/G	19.8	22.5	25.0				
		G/G	0.9	0.8	1.1				
		Allele frequency	14.4	12.0	13.6	0.863	1.09 (0.54–2.18)	0.620	1.25 (0.64–2.45)
	rs1254598	A/A	70.7	67.1	65.1	0.027 pc = 0.103	0.10 (0.01–0.94)	0.271	1.31 (0.81–2.12)
		A/G	26.7	32.5	31.6				
		G/G	2.6	0.4	3.3				
		Allele frequency	15.9	16.6	19.1	0.980	1.04 (0.57–1.89)	0.569	1.21 (0.68–2.15)
	rs1353411	G/G	71.3	66.5	66.0	0.760	1.09 (0.63–1.87)	0.300	1.29 (0.79–2.10)
		G/A	22.6	30.1	30.6				
		A/A	6.1	3.4	3.3				
		Allele frequency	17.4	18.4	18.6	0.883	1.09 (0.61–1.95)	0.776	1.10 (0.62–1.95)
	rs2075797	C/C	81.7	79.1	75.3	0.640	1.16 (0.62–2.20)	0.151	1.49 (0.85–2.61)
		C/G	16.5	20.1	23.6				
		G/G	1.7	0.8	1.1				
		Allele frequency	9.9	10.8	12.9	0.978	1.05 (0.51–2.16)	0.610	1.27 (0.63–2.55)
PTGER3	rs959	Т/Т	68.7	70.8	62.7	0.940	0.98 (0.55–1.73)	0.210	1.35 (0.84–2.18)
		C/T	28.7	24.1	35.1				
		C/C	2.6	5.0	2.2				
		Allele frequency	16.9	17.0	19.7	0.980	0.98 (0.53–1.80)	0.671	1.18 (0.67–2.08)
PTGER4	rs4495224	A/A	36.8	41.0	46.5	0.400	0.80 (0.48–1.35)	0.067	0.65 (0.41–1.03)
Allele freque NERD: NSAID	ncy represents the r is-exacerbated resp	minor allele frequency for ea iratory disease; NS: Not sigr	ach SNP. iificant; NTA:	NSAID-tole	ant asthmatic p	atients; OR: Odds ratio.			

Table 2.	Genotype and	minor allele freque	ncies of t	ne SNPS I	n aracnidoi	nic acid pathway ge	nes (cont.).		
Gene	SNP	Genotype	NERD	NTA	Controls	NERD	vs NTA	NERD V	s controls
						p-value	OR (95% CI)	p-value	OR (95% CI)
PTGER4	rs4495224	A/C	50.0	47.3	45.4				
(cont.)	(cont.)	C/C	13.2	11.7	8.1				
		Allele frequency	38.2	35.3	30.8	0.637	0.88 (0.55–1.39)	0.046 pc = 0.170	0.75 (0.57–0.99)
	rs7720838	Т/Т	27.2	27.9	32.7	0.610	0.86 (0.48–1.52)	0.230	0.74 (0.45–1.21)
		D/L	47.4	51.4	47.4				
		G/G	25.4	20.7	19.9				
		Allele frequency	49.0	46.0	43.6	0.646	0.90 (0.57–1.41)	0.370	0.81 (0.52–1.25)
	rs45613037	G/G	26.1	22.6	22.4	0.008 pc = 0.046	2.41 (1.22–4.76)	0.410	1.24 (0.74–2.09)
		G/A	56.5	50.2	50.7				
		A/A	17.4	27.1	26.8				
		Allele frequency	45.6	52.2	52.0	0.029 pc = 0.011	1.35 (1.03–1.77)	0.317	1.28 (0.82–1.98)
PTGFR	rs3753380	C/C	44.4	57.6	52.9	0.015 pc = 0.071	0.63 (0.43–0.92)	0.020 pc = 0.09	0.58 (0.37–0.92)
		C/T	47.0	34.9	36.4				
		Т/Т	8.7	7.5	10.7				
		Allele frequency	32.2	25.0	28.9	0.024 pc = 0.099	0.71 (0.53–0.95)	0.546	0.86 (0.54–1.38)
Allele freque NERD: NSAIC	ncy represents the r)s-exacerbated resp	minor allele frequency for ei iratory disease; NS: Not sigr	ach SNP. ifficant; NTA:	NSAID-toler	ant asthmatic p	atients; OR: Odds ratio.			

Research Article Ayuso, Plaza-Serón, Blanca-López et al.

for two-tailed associations for the presence of the SNPs (MAF = 0.1) identified in this study was 87.0%.

The study was conducted according to the principles of the Declaration of Helsinki. All participating patients gave their informed consent and protocols were approved by the ethics committees of the institutions involved in the study.

Results

The study included a total of 250 Caucasian NERD patients, 260 NTA subjects and 315 unrelated, ethnically matched healthy subjects. No statistically significant differences were found between the three groups for age or sex (Table 1). The most frequent clinical entity in the NERD group was asthma only (57.6%) followed by rhinitis and asthma (22.4%). Propionic acid derivatives were the most frequent culprit drugs (31.6%), followed by ASA (26.0%) and pyrazolones (18.70%) (Table 1). Regarding the atopic status, we found statistically significant differences in SPT results between NERD patients and controls (Table 1).

Out of the 33 SNPs studied, 17 were in genes encoding enzymes from the arachidonic acid pathway and 16 were in genes encoding CysLT and prostaglandin receptors. No significant deviation from Hardy–Weinberg equilibrium was found for any of the SNPs in controls.

Genotypic frequencies are shown in Table 2. We found three statistically significant associations according to a dominant genetic model: *ALOX15* rs3892408 C/C homozygous genotype (NERD vs NTA; OR: 3.29; p = 0.0001, pc = 0.0011; NERD vs controls; OR: 3.48; p = 0.0001, pc = 0.0011), *PTGS1* rs5789 A/A homozygous genotype (NERD vs NTA; OR: 0.28; p = 0.0001, pc = 0.0011; NERD vs controls; OR: 0.01; p = 0.0001, pc = 0.0011), *PTGS1* rs10306135 A/A homozygous genotype (NERD vs NTA; OR: 2.19; p = 0.0009, pc = 0.0091; NERD vs controls; OR: 2.12; p = 0.0064, pc = 0.045).

When the allelic model was considered statistical significant differences were also observed for the SNPs *ALOX15* rs3892408 (NERD vs NTA; OR: 1.83; p = 0.0001, pc = 0.0011; NERD vs controls; OR: 2.00; p = 0.0001, pc = 0.0011), *PTGS1* rs5789 (NERD vs NTA; OR: 0.33; p = 0.0001, pc = 0.0011; NERD vs controls; OR: 0.01; p = 0.0001, pc = 0.0011) and *PTGS1* rs10306135 (NERD vs NTA; OR: 1.73; p = 0.0080, pc = 0.046; NERD vs controls; OR: 1.65; p = 0.0081, pc = 0.046). In addition, these three SNPs were not in linkage disequilibrium in this population [rs3892408-rs5789 ($r^2 = 0.003$) and rs3892408-rs10306135 ($r^2 = 0.001$].

Other SNPs in CYSLTR1 rs320995, PTGER1 rs3810253 and PTGER1 rs3810255 showed signifi-

cantly different distributions of genotypes and allele frequencies in NERD and control subjects, but not when NERD and NTA patients were compared.

We found three statistically significant associations following FDR multiple testing correction. Moreover, when using a more conservative correction such as Bonferroni, the associations of *ALOX15* rs3892408, *PTGS1* rs5789 and *PTGS1* rs10306135 remained statistically significant according to a dominant genetic model.

In order to further evaluate the possible functional effects of these three significant SNPs (rs3892408, rs5789 and rs10306135), we analyzed their association with the following clinical parameters: eosinophil count, eosinophil cationic protein and tryptase serum levels. However, we could not find any association between these three SNPs and changes in these clinical parameters between NERD and controls (data not shown).

We also analyzed the association of CNVs in *PTGS1, PTGS2, LTC4S, ALOX5* and *PTGER1–4* with NERD (Table 3). All control subjects had two copies of each gene analyzed. Regarding NERD patients, we identified significant differences between the different groups for *ALOX5*: NERD vs NTA (OR: 0.17; p = 0.010), NERD vs controls (OR: 0.03; p = 0.0001). We also found three NERD individuals with one copy of the *LTC4S* gene, although these differences were not significant compared with controls.

Discussion

NERD has long been the most highly studied model of NSAID hypersensitivity with a large number of association studies of genetic variants published in the last few years, which have mainly focused on genes related to the arachidonic acid pathway [17]. However, in many of these studies, the associations were inconsistently replicated and the number of gene variants was limited [17]. Genome wide association studies (GWAS) have also been carried out. The first GWAS was carried out in a small cohort of Korean NERD patients, where the authors found an association for SNPs in the CEP68 gene and confirmed the association of several others [30]. More recently, another GWAS in Korean NERD patients showed the HLA-DPB1 rs1042151 polymorphism to be a putative genetic factor [31]. Nevertheless, there is a lack of genetic association studies for this clinical entity in Spanish populations. Recently, we have reported a genetic study involving variants of CEP68 and HDR to NSAIDs for NIUA, NERD and blended phenotype patients [32]. We have also reported a study that found genetic variants involved in arachidonic acid pathways that were associated with NIUA [18]. These findings support that using a small number of SNPs selected based on evidence from previous studies of hypersensitivity reactions to NSAIDs and related phenotypes can be used to search for genetic variants associated with the related pathology NERD.

In this study, we found significant association between NERD and a number of SNPs in genes related to arachidonic acid pathways, including *ALOX15* and *PTGS1*.

These genes are important in the first steps of arachidonic acid metabolism (see Figure 1). This lipid can be metabolized by different pathways including lipoxygenases (5-LOX, 15-LOX and 12-LOX), PTGS (PTGS-1 and PTGS-2), cytochrome oxidases and nonenzymatic pathways [33].

Concerning the lipoxygenases pathway, *ALOX15* encodes 15-lipoxygenase (15-LOX), an iron metalloenzyme that catalyzes the generation of the proinflammatory metabolites eoxins [34] and lipoxin 15-hydroxyeicosatetraenoic acid (15-HETE), a precursor of active lipoxins and functional antagonists of CysLTs [14,35]. In presence of L-ASA, eosinophils activated from NERD patients generate higher levels of lipoxin 15-HETE and eoxin EXC4 [36]. Also, exhaled 15-HETE levels have been shown to be higher at baseline in NERD than in NTA subjects [37]. Thus, the activation of 15-LOX appears to be an important step

in 15-HETE generation by ASA in NERD patients [38]. Moreover, 15-LOX catalyzes the main formation route of resolvins, lipid mediators characterized by their anti-inflammatory and proresolving properties [39,40]. Moreover, PTGS-2 has been shown to enhance resolvin formation under the ASA therapy [41]. In this context, SNPs in ALOX15 could act by modulating eicosanoid generation in NERD patients. We found an association between the NERD and the ALOX15 rs3892408 polymorphism, which gives rise to the missense amino acid substitution Val239Met located in a metal-binding protein domain [42]. Whether this association implies an impaired 15-LOX function in NERD patients requires further research. Recently, a haplotype comprising promoter polymorphisms of ALOX15 was found to be associated with NERD and related to increased eosinophil infiltration in Korean patients [43]. Nevertheless, to our knowledge, this is the first study that shows an association between the nonsynonymous ALOX15 rs3892408 polymorphism and NERD.

Population frequency data for the SNP rs3892408 are scarce. The data available on NCBI show a minor allele frequency of 0.40, similar to our reported a minor allele frequency in the control group of 0.48. Our findings show a significant association between this SNP and NERD patients (NERD vs NTA; OR:

Table 3. C	opy number NTA subjec	variatio ts.	ns in PT(GS1, PTGS2,	LTC4S, AL	OX5 and PTGER1	-4 genes iı 	n controls,
Gene	N° copies	NERD	NTA	Controls	NEF	RD vs NTA	NERD	vs controls
					p-value	OR (95% CI)	p-value	OR (95% CI)
PTGS1	2 copies	250	260	315	NS		NS	
	1 сору	0	0	0				
PTGS2	2 copies	250	260	315	NS		NS	
	1 сору	0	0	0				
LTC4S	2 copies	247	258	315	NS		NS	
	1 сору	3	2	0				
ALOX5	2 copies	239	258	315	0.010	0.17 (0.0–0.8)	0.0001	0.03 (0.0–0.5)
	1 сору	11	2	0				
PTGER1	2 copies	250	257	315	NS		NS	
	1 сору	0	3	0				
PTGER2	2 copies	250	260	315	NS		NS	
	1 сору	0	0	0				
PTGER3	2 copies	250	260	315	NS		NS	
	1 сору	0	0	0				
PTGER4	2 copies	250	260	315	NS		NS	
	1 сору	0	0	0				
NERD: NSAIDs	-exacerbated res	piratory dise	ease; NTA: N	NSAID-tolerant a	asthmatic pati	ents; NS: Not significant	t; OR: Odds ra	itio.



Figure 1. Arachidonic acid metabolic pathway: the metabolites involved in the NERD pathology are indicated in rectangles. The enzymes and receptors in which encoding genes have been analyzed in this study are indicated in light turquoise. The enzymes in which encoding genes have shown association with NERD in this study are indicated in dark turquoise. NERD: NSAIDs-exacerbated respiratory disease.

2.49; p = 0.0001, pc = 0.0011; NERD vs controls; OR: 2.83; p = 0.0001, pc = 0.0011); even adjusting for atopic status (NERD vs NTA; OR: 3.29; p = 0.0001, pc = 0.0011; NERD vs controls; OR: 3.48; p = 0.0001, pc = 0.0011). The H-W equilibrium is maintained in the NERD subjects (p = 0.430) and is slightly off for these patients when they are adjusted for atopic status (p = 0.032). These patients and controls have been genotyped by PCR using TaqMan allelic discrimination assays in triplicate, minimizing the likelihood of this being due to technical error. However, we are currently recruiting more NERD patients in order to validate these findings in a larger series of patients, as recommended by the NCI-NHGRI Working Group on Replication in Association Studies [44]. Although several SNPs in *ALOX5AP*, *ALOX5* and *ALOX12* have been shown to be related to chronic rhinosinusitis and/or asthma [45,46], we did not find statistical significant differences between NERD, NTA and healthy subjects.

Concerning the cyclooxygenases pathway, *PTGS1* encodes the PTGS-1 enzyme that catalyzes the conversion of arachidonic acid to prostaglandins, prostacyclins and thromboxane. NSAIDs inhibit its activity, leading to CysLTs overproduction in NERD patients, which is considered the trigger of NSAID hypersensitivity [12]. The PTGS-1 isoform is constitutively expressed by almost all tissues involved in homeostasis [47]. Despite this fact, some studies have found a small increase in its expression under inflammatory conditions [48]. Human

bronchial epithelial cells from NERD patients show a downregulation of PTGS-1-mRNA [49] and an altered regulation of *PTGS1* in nasal polyps from NERD patients has been suggested to contribute to the low levels of PGE₂ detected in these patients [50]. Moreover, the cyclooxygenase pathway results in the formation of other prostaglandins and higher concentration of PGD₂ in the sputum of NERD patients than in NTA and healthy subjects has been reported [51].

Therefore, *PTGS1* SNPs could contribute to the underlying mechanism of NERD. In this study, we found that the rs10306135 polymorphism was associated with NERD. This SNP is located close to the promoter region of *PTGS1*, and therefore may affect gene expression [52]. Nevertheless, there are no *in vitro* or *in vivo* functional studies evaluating the effect of this SNP.

For the rs5789 *PTGS1* polymorphism, we have found that the minor allele is more common in NERD patients than in NTA and control subjects. Interestingly, this allele has been shown to be related to a decrease of arachidonic acid metabolism in hemodynamic responses in the neurovascular system [53], although the effect of a decreased function in PTGS-1 caused by rs5789 has not been studied in NERD patients. Further functional studies are needed to elucidate the role of these SNPs in the underlying mechanism of NERD.

CysLTs contribute to inflammation and are effectors of the symptoms that characterize NERD patients [5]; therefore, we analyzed polymorphisms in the LTC4S, CYSLTR1 and CYSLTR2 genes. Although the SNP rs730012 in LTC4S has been shown to be associated with NERD in both Polish and Japanese populations [54,55], we found no association, in common with other studies in different ethnic groups [56,57]. The effects of CysLTs may be modulated by genetic variation in their receptors, supporting this hypothesis the polymorphism rs912278 in CYSLTR2, which affects the transcription and stability of CYSLTR2 mRNA has been found to be associated with NERD in a Korean population [58]. Nevertheless, this association was not found in this study. With regard to prostaglandin receptors, associations have been found for variants in PTGER2, PTGER3 and PTGER4 in Japanese and Korean populations [59-61]. We analyzed these SNPs and other functional polymorphisms [62-64]; however, these associations were not found in our population. Considering the PTGFR rs3753380 SNP, our findings show that the minor allele is more frequent in NERD patients. This allele is related to a lower transcriptional activity of the PTGFR gene [64]. However, when we adjust for multiple comparisons, this association did not remain statistically significant.

Finally, we investigated CNVs in *PTGS1–2*, *LTC4S*, *ALOX5* and *PTGER1–4*. To the best of our knowledge, this is the first time that CNVs have been studied

in NSAID hypersensitivity. We found an association between CNVs in *ALOX5* and NERD patients. 5-LOX catalyzes leukotriene and lipoxin production, playing a key role in pathogenesis of NERD [35]. Further studies are required to investigate the potential functional effect of the CNVs in the *ALOX5* gene found here.

These associations were not found in a previous study of Spanish NIUA patients, suggesting that NERD and NIUA may have different underlying mechanisms at the molecular level [18]. However, more studies including both larger sample sizes and more genetic variants are needed to further explore this hypothesis.

Conclusion

We found significant associations for common genetic variants in genes related to the arachidonic acid pathway in a well-phenotyped group of Spanish NERD patients. This is the first work evaluating both SNPs and CNVs in genes encoding enzymes and receptors from the arachidonic acid pathway for NSAIDs-hypersensitivity patients.

Future perspective

NSAIDs are one of the most highly used medicines and it is estimated that tens of millions of individuals worldwide consume them daily [65]. They are also the most frequent drugs involved in HDR [3]. Therefore, NSAID hypersensitivity constitutes an important health problem. Focusing on NERD, its prevalence reaches 14.89% among patients with severe asthma [66]. Currently, a drug provocation test is required for the accurate diagnosis of NERD, which has a number of drawbacks. Thus, knowledge of genetic markers that can provide information about susceptibility to this disorder may consequently help minimize patient risk by providing an alternative diagnosis tool. In this study, we report that certain genetic variants in genes involved in arachidonic acid metabolism are associated with NERD. Future studies will complement genetic studies by adding information on gene expression and methylation [67]. These advances will help us to unravel the full genetic basis of the disease, the relationship between genotype and phenotype, and to establish novel diagnostic techniques for HDRs to NSAIDs, an important step in the development of personalized medicine.

Financial & competing interests disclosure

This study was supported by grants from the Spanish Health Ministry Fund for Health in Spain (FIS) network RIRAAF (RD012/0013), PI12/02247 and PI13/02598. JR Perkins is a researcher from the Sara Borrell Program (Ref CD14/00242, Carlos III National Healthy Institute, Spanish Ministry of Economy and Competitiveness). This work has been partially supported by the European Commission though the FP7 IAPP project Mr.SymBioMath (project code: 324554). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Ethical conduct of research

The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

No writing assistance was utilized in the production of this manuscript.

Executive summary

Results

- Significant associations were found between ALOX15 SNP rs3892408 and PTGS1 SNPs (rs10306135 and rs5789) and the risk of NSAIDs-exacerbated respiratory disease (NERD) in a Spanish population.
- Copy number variations (CNVs) were analyzed for *PTGS1*, *PTGS2*, *LTC4S*, *ALOX5*, *PTGER1*, *PTGER2*, *PTGER3* and *PTGER4* genes. This is the first time such work has been conducted for NERD. No CNVs were found in healthy control subjects.
- ALOX5 CNVs occur in NERD subjects (4.6%) and NSAID-tolerant asthmatic patients (NTA; 0.8%), and there are statistically significant differences between NERD patients, NTA and controls. These CNVs are attributable to gene deletion.
- *LTC4S* CNVs are less frequent in NERD and NTA subjects and these differences were not significant compared with controls. These CNVs are attributable to gene deletion.

Conclusion

• This study shows several associations between common genetic variants, including SNPs and CNVs, in genes related to the arachidonic acid pathway and the risk of NSAIDs-exacerbated respiratory disease in a Spanish population.

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

- Rubio M, Bousquet PJ, Gomes E, Romano A, Demoly P. Results of drug hypersensitivity evaluations in a large group of children and adults. *Clin. Exp. Allergy* 42(1), 123–130 (2012).
- 2 Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 71(5), 684–700 (2011).
- 3 Doña I, Blanca-Lopez N, Torres MJ et al. Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J. Invest. Allergol. Clin. Immunol. 22(5), 363–371 (2012).
- Detailed study of drug hypersensitivity reactions in a large series of Spanish patients.
- 4 Stevenson DD, Sanchez-Borges M, Szczeklik A. Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. *Ann. Allergy Asthma Immunol.* 87(3), 177–180 (2001).
- 5 Kowalski ML, Asero R, Bavbek S et al. Classification and practical approach to the diagnosis and management of hypersensitivity to nonsteroidal anti-inflammatory drugs. *Allergy* 68(10), 1219–1232 (2013).
- Clinical classification of hypersensitivity reactions to NSAIDs.
- 6 Doña I, Blanca-Lopez N, Cornejo-Garcia JA et al. Characteristics of subjects experiencing hypersensitivity to non-steroidal anti-inflammatory drugs: patterns of response. *Clin. Exp. Allergy* 41(1), 86–95 (2011).

- 7 Ayuso P, Blanca-Lopez N, Dona I *et al.* Advanced phenotyping in hypersensitivity drug reactions to NSAIDs. *Clin. Exp. Allergy* 43(10), 1097–1109 (2013).
- 8 Lee RU, Stevenson DD. Aspirin-exacerbated respiratory disease: evaluation and management. *Allergy Asthma Immunol. Res.* 3(1), 3–10 (2011).
- 9 Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. *BMJ* 328(7437), 434 (2004).
- Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. *Eur. Respir. J.* 16(3), 432–436 (2000).
- 11 Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. *Ann. Allergy Asthma Immunol.* 89(5), 474–478 (2002).
- 12 Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. *Br. Med. J.* 1(5949), 67–69 (1975).
- Role of arachidonic acid metabolism in NSAIDsexacerbated respiratory disease (NERD) patients.
- 13 Kowalski ML, Pawliczak R, Wozniak J et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am. J. Respir. Crit. Care Med. 161(2 Pt 1), 391–398 (2000).
- 14 Celik G, Bavbek S, Misirligil Z, Melli M. Release of cysteinyl leukotrienes with aspirin stimulation and the effect of prostaglandin E(2) on this release from peripheral blood

leucocytes in aspirin-induced asthmatic patients. *Clin. Exp. Allergy* 31(10), 1615–1622 (2001).

- 15 Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. *Am. J. Respir. Cell. Mol. Biol.* 23(3), 290–296 (2000).
- Description of a genetic variant related to leukotriene homeostasis and its effect in NERD patients.
- 16 Oh JM, Kim SH, Suh CH *et al.* Lack of association of glutathione S-transferase P1 Ile105Val polymorphism with aspirin-intolerant asthma. *Korean J. Intern. Med.* 20(3), 232–236 (2005).
- 17 Park SM, Park JS, Park HS, Park CS. Unraveling the genetic basis of aspirin hypersensitivity in asthma beyond arachidonate pathways. *Allergy Asthma Immunol. Res.* 5(5), 258–276 (2013).
- •• Updated and detailed review on genetic basis of NERD.
- 18 Cornejo-Garcia JA, Jagemann LR, Blanca-Lopez N et al. Genetic variants of the arachidonic acid pathway in nonsteroidal anti-inflammatory drug-induced acute urticaria. *Clin. Exp. Allergy* 42(12), 1772–1781 (2012).
- •• Identification of genetic variants of the arachidonic acid metabolism in a clinical entity of NSAID hypersensitivity.
- Fanciulli M, Petretto E, Aitman TJ. Gene copy number variation and common human disease. *Clin. Genet.* 77(3), 201–213 (2010).
- 20 Bateman ED, Hurd SS, Barnes PJ *et al.* Global strategy for asthma management and prevention: GINA executive summary. *Eur. Respir. J.* 31(1), 143–178 (2008).
- 21 Campo P, Ayuso P, Salas M *et al.* Mediator release after nasal aspirin provocation supports different phenotypes in subjects with hypersensitivity reactions to NSAIDs. *Allergy* 68(8), 1001–1007 (2013).
- 22 Palikhe NS, Kim SH, Cho BY, Ye YM, Hur GY, Park HS. Association of three sets of high-affinity IgE receptor (FcepsilonR1) polymorphisms with aspirin-intolerant asthma. *Respir. Med.* 102(8), 1132–1139 (2008).
- 23 Frazer KA, Ballinger DG, Cox DR et al. A second generation human haplotype map of over 3.1 million SNPs. *Nature* 449(7164), 851–861 (2007).
- 24 Abecasis GR, Altshuler D, Auton A *et al.* A map of human genome variation from population-scale sequencing. *Nature* 467(7319), 1061–1073 (2010).
- 25 Database of Single Nucleotide Polymorphisms (dbSNP). National Center for Biotechnology Information, National Library of Medicine, Bethesda, MD, USA. (dbSNP Build ID: {build ID}). www.ncbi.nlm.nih.gov/SNP/
- 26 Xu Z, Taylor JA. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. *Nucleic Acids Res.* 37, W600–W605 (2009).
- 27 DeFinetti program. http://ihg2.helmholtzmuenchen.de/cgi-bin/hw/hwa1.pl

- 28 Storey J. A direct approach to false discovery rates. J. R. Stat. Soc. B 64, 479–498 (2002).
- 29 Barrett JC. Haploview: visualization and analysis of SNP genotype data. *Cold Spring Harb. Protoc.* 2009 (10), pdb ip71 (2009).
- 30 Kim JH, Park BL, Cheong HS *et al.* Genome-wide and followup studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. *PLoS ONE* 5(11), e13818 (2010).
- •• First genome-wide study developed in NERD patients.
- 31 Park BL, Kim TH, Kim JH *et al.* Genome-wide association study of aspirin-exacerbated respiratory disease in a Korean population. *Hum. Genet.* 132(3), 313–321 (2013).
- 32 Cornejo-Garcia JA, Flores C, Plaza-Seron MC et al. Variants of CEP68 gene are associated with acute urticaria/angioedema induced by multiple non-steroidal anti-inflammatory drugs. *PLoS ONE* 9(3), e90966 (2014).
- 33 Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to *in vivo* tissue responses. *Pharmacol. Rev.* 58(3), 375–388 (2006).
- 34 Feltenmark S, Gautam N, Brunnstrom A *et al*. Eoxins are proinflammatory arachidonic acid metabolites produced via the 15-lipoxygenase-1 pathway in human eosinophils and mast cells. *Proc. Natl Acad. Sci. USA* 105(2), 680–685 (2008).
- 35 Narayanankutty A, Resendiz-Hernandez JM, Falfan-Valencia R, Teran LM. Biochemical pathogenesis of aspirin exacerbated respiratory disease (AERD). *Clin. Biochem.* 46(7–8), 566–578 (2013).
- 36 James A, Daham K, Backman L *et al.* The influence of aspirin on release of eoxin C4, leukotriene C4 and 15-HETE, in eosinophilic granulocytes isolated from patients with asthma. *Int. Arch. Allergy Immunol.* 162(2), 135–142 (2013).
- 37 Mastalerz L, Sanak M, Kumik J *et al.* Exhaled eicosanoids following bronchial aspirin challenge in asthma patients with and without aspirin hypersensitivity: the pilot study. *J. Allergy* (*Cairo*) 2012, 696792 (2012).
- 38 Jedrzejczak-Czechowicz M, Lewandowska-Polak A, Bienkiewicz B, Kowalski ML. Involvement of 15-lipoxygenase and prostaglandin EP receptors in aspirin-triggered 15-hydroxyeicosatetraenoic acid generation in aspirin-sensitive asthmatics. *Clin. Exp. Allergy* 38(7), 1108–1116 (2008).
- 39 Serhan CN. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? *Am. J. Pathol.* 177(4), 1576–1591 (2010).
- 40 Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. *Chem. Rev.* 111(10), 5922–5943 (2011).
- 41 Sun YP, Oh SF, Uddin J *et al.* Resolvin D1 and its aspirintriggered 17R epimer. Stereochemical assignments, antiinflammatory properties, and enzymatic inactivation. *J. Biol. Chem.* 282(13), 9323–9334 (2007).
- 42 RecName: Full=Arachidonate 15-lipoxygenase; Short=15-LOX; Short=15-LOX-1; AltName: Full=12/15-lipoxygenase; AltName: Full=Arachidonate 12-lipoxygenase, leukocytetype; Short=12-LOX; AltName: Full=Arachidonate omega-6 lipoxygenase [*Homo sapiens*]. www.ncbi.nlm.nih.gov

Arachidonic acid pathway variants in NERD Research Article

- 43 Song YS, Yang EM, Kim SH, Jin HJ, Park HS. Effect of genetic polymorphism of ALOX15 on aspirin-exacerbated respiratory disease. *Int. Arch. Allergy Immunol.* 159(2), 157–161 (2012).
- 44 Chanock SJ, Manolio T, Boehnke M *et al.* Replicating genotype-phenotype associations. *Nature* 447(7145), 655–660 (2007).
- 45 Lima Jj, Zhang S, Grant A *et al.* Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. *Am. J. Respir. Crit. Care Med.* 173(4), 379–385 (2006).
- 46 Al-Shemari H, Bosse Y, Hudson TJ *et al.* Influence of leukotriene gene polymorphisms on chronic rhinosinusitis. *BMC Med. Genet.* 9, 21 (2008).
- 47 Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. *Pharmacol. Rev.* 56(3), 387–437 (2004).
- 48 Mcadam BF, Mardini IA, Habib A *et al.* Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. *J. Clin. Invest.* 105(10), 1473–1482 (2000).
- 49 Pierzchalska M, Soja J, Wos M *et al.* Deficiency of cyclooxygenases transcripts in cultured primary bronchial epithelial cells of aspirin-sensitive asthmatics. *J. Physiol. Pharmacol.* 58(2), 207–218 (2007).
- 50 Roca-Ferrer J, Garcia-Garcia FJ, Pereda J et al. Reduced expression of COXs and production of prostaglandin E(2) in patients with nasal polyps with or without aspirin-intolerant asthma. J. Allergy Clin. Immunol. 128(1), 66–72, e61 (2011).
- 51 Higashi N, Taniguchi M, Mita H, Osame M, Akiyama K. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. *Clin. Exp. Allergy* 32(10), 1484–1490 (2002).
- 52 Helmersson J, Arnlov J, Axelsson T, Basu S. A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2alpha formation and lower risk of cardiovascular disease. *Prostaglandins Leukot. Essent. Fatty Acids* 80(1), 51–56 (2009).
- 53 Hahn T, Heinzel S, Plichta MM, Reif A, Lesch KP, Fallgatter AJ. Neurovascular coupling in the human visual cortex is modulated by cyclooxygenase-1 (COX-1) gene variant. *Cereb. Cortex* 21(7), 1659–1666 (2011).
- 54 Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. *Lancet* 350(9091), 1599–1600 (1997).
- 55 Kawagishi Y, Mita H, Taniguchi M *et al.* Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. *J. Allergy Clin. Immunol.* 109(6), 936–942 (2002).

- 56 Van Sambeek R, Stevenson DD, Baldasaro M et al. 5' flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirinintolerant asthma phenotype in the United States. J. Allergy Clin. Immunol. 106(1 Pt 1), 72–76 (2000).
- 57 Choi JH, Park HS, Oh HB *et al.* Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase. *Hum. Genet.* 114(4), 337–344 (2004).
- 58 Park JS, Chang HS, Park CS et al. Association analysis of cysteinyl-leukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. *Pharmacogenet. Genomics* 15(7), 483–492 (2005).
- 59 Jinnai N, Sakagami T, Sekigawa T *et al.* Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. *Hum. Mol. Genet.* 13(24), 3203–3217 (2004).
- 60 Kim SH, Choi JH, Park HS *et al.* Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. *Clin. Exp. Allergy* 35(5), 585–590 (2005).
- 61 Park BL, Park SM, Park JS *et al.* Association of PTGER gene family polymorphisms with aspirin intolerant asthma in Korean asthmatics. *BMB Rep.* 43(6), 445–449 (2010).
- 62 Serre D, Gurd S, Ge B *et al.* Differential allelic expression in the human genome: a robust approach to identify genetic and epigenetic cis-acting mechanisms regulating gene expression. *PLoS Genet.* 4(2), e1000006 (2008).
- 63 Libioulle C, Louis E, Hansoul S et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. *PLoS Genet.* 3(4), e58 (2007).
- 64 Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. *Ophthalmology* 114(6), 1039–1045 (2007).
- 65 Abramson SB. Clinical guidelines: Expert recommendations for NSAID use: a user-friendly model? *Nat. Rev. Rheumatol.* 7(3), 133–134 (2011).
- 66 Rajan JP, Wineinger NE, Stevenson DD, White AA. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. *J. Allergy Clin. Immunol.* 135(3), 676–668 (2014).
- 67 Perkins JR, Sanak M, Canto G, Blanca M, Cornejo-Garcia JA. Unravelling adverse reactions to NSAIDs using systems biology. *Trends Pharmacol. Sci.* 36(3), 172–180 (2015).